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ABSTRACT 
 
Self-renewal is essential for stem cell maintenance. In the blood system, rare 
hematopoietic stem cells (HSCs) must maintain their self-renewal potential to sustain 
long-term homeostasis. HSC self-renewal is tightly regulated, as defective self-renewal 
can result in stem cell depletion and unrestricted self-renewal is a hallmark of leukemia. 
In this report, we describe two novel regulators of HSC self-renewal illustrative of the 
diverse mechanisms that sustain stable long-term blood formation. 
Absent, small, or homeotic 1-like (Ash1l) is a Trithorax group (TrG) member with 
a previously uncharacterized physiological function. The TrG is of interest in 
hematopoiesis, as Mixed-lineage leukemia 1, the prototypical TrG member, is required 
for HSC maintenance and frequently drives human leukemogenesis. Our work 
demonstrates that HSCs require Ash1l for establishing quiescence in the bone marrow, a 
fundamental process for preservation of HSC self-renewal. In the absence of Ash1l, HSCs 
become depleted in the young adult bone marrow, and HSC function is not detected in 
transplantation assays. Despite an apparent lack of functional HSCs, Ash1l-deficient mice 
do not progress to hematopoietic failure elucidating a paradoxical preservation of steady-
state hematopoiesis despite a lack of transplantable HSC function. Additionally, we 
found that Ash1l cooperates non-redundantly with Mll1 to maintain hematopoietic 
homeostasis. This is reminiscent of the functional cooperativity that defines Drosophila 
TrG members and has not been demonstrated in mammals.   
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Adrenocortical dysplasia (Acd), encodes Tpp1, a member of the telomere-
protecting shelterin protein complex. Recent work implicates shelterin in a particularly 
aggressive form of the human bone marrow failure syndrome dyskeratosis congenita, 
though roles for shelterin proteins in hematopoietic homeostasis have not been fully 
defined. Our work indicates that Acd loss causes acute hematopoietic stem and progenitor 
cell depletion and severely impaired HSC self-renewal in transplantation assays. Though 
Acd deletion results in p53 target gene activation, p53 deletion is not sufficient to rescue 
Acd-deficient HSC function. This is contrary to models of Acd deficiency in other stem 
cell systems in which p53 inactivation largely rescues function. Our data suggest that 
HSCs are exquisitely sensitive to Acd loss and that shelterin proteins have previously 
undefined context-dependent functions in stem cell biology. 
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CHAPTER 1.  HEMATOPOIETIC STEM CELL DEVELOPMENT, 
SELF-RENEWAL, AND FUNCTION 
* 
HISTORICAL BACKGROUND TO THE STUDY OF HEMATOPOIETIC STEM CELLS 
In the early 1950s, researchers observed that bone marrow transplantation could 
rescue hematopoietic failure in lethally irradiated animals [1]. This was of particular 
interest amidst growing concerns about the threat of radiation exposure following the 
Manhattan Project and the subsequent bombings of Hiroshima and Nagasaki [2]. Initially, 
hematopoietic rescue was attributed to “humoral factors” that were present in the donor 
bone marrow and could revitalize the irradiated host’s damaged marrow [3]. Prior to 
establishing an experimental understanding of the nature of this hematopoietic rescue, 
two reports demonstrated that this finding had translational potential in human medicine. 
The first described a group of physicists who were accidentally exposed to a high dose of 
radiation, but recovered faster and better than expected after an infusion of donor bone 
marrow, probably as a result of transient engraftment [4]. The second report described 
two cases of leukemia patients who were treated with lethal irradiation and then 
transplanted with bone marrow from an identical twin sibling [5]. Hematopoietic function 
was restored by the procedure. While these isolated reports highlighted the promise of 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  *	  Material in this chapter is partially covered in:  
Sandy, A. R., Jones, M., and Maillard I., Notch signaling and development of the 
hematopoietic system. In:  Notch signaling in embryology and cancer.  Jorg Reichrath 
and Sandra Reichrath (eds.). Springer. 2011.	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bone marrow transplantation, there was a limited understanding at this stage about the 
mechanisms of hematopoietic rescue after bone marrow infusion. 
In 1961, seminal experiments by Till and McCulloch demonstrated that the source 
of hematopoietic rescue in mouse transplantation models was cellular and not humoral 
[6]. Following irradiation and subsequent bone marrow transplantation, it was noted that 
discrete colonies could be enumerated in the spleens of murine recipients.  These colonies 
contained multiple lineages of hematopoietic cells, and were directly proportional to the 
number of nucleated bone marrow cells injected into the animal. Furthermore, the cells 
responsible for forming these colonies were rare, estimated at ~ 1 in 1,000 bone marrow 
cells. Further insight into the origin of these hematopoietic colonies was provided by the 
demonstration that each colony arose from a single cell, suggesting that the bone marrow 
housed a primitive cell type that could differentiate into multiple blood lineages [7].  
The notion that rare, transplantable, multipotent cells could be the source of 
hematopoietic recovery in transplant recipients laid the groundwork for the study of what 
became known as hematopoietic stem cells (HSCs). Soon after their initial identification, 
these rare colony-forming cells were shown to have extensive self-renewal potential [8, 
9]. Indeed, when splenic colonies were harvested, processed, and re-transplanted into a 
secondary recipient, new colonies would form. This suggested that the colony-initiating 
cells, now termed HSCs, could divide while maintaining their own identity and giving 
rise to differentiated progeny. This asymmetric mode of cell division is the hallmark of 
stem cell populations. The serial transplantation approach described in these studies 
remains similar to gold standard methods for testing HSC self-renewal to this day. 
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In the 50 years since the discovery of bone marrow HSCs, investigators have 
made significant progress toward understanding the mechanisms by which HSCs 
maintain their function. We now know that HSCs utilize many mechanisms to balance 
self-renewal and differentiation, and that this balance is critical to hematopoietic 
homeostasis. In this chapter, we will review our current understanding of HSC 
development and the multifactorial mechanisms through which self-renewal is regulated. 
HEMATOPOIETIC STEM CELL EMERGENCE AND DEVELOPMENT 
Hematopoiesis is initiated in two distinct waves. The first or “primitive” wave 
originates in the extra-embryonic yolk sac and is primarily responsible for the 
development of erythroid cells required for gas exchange during mid-gestation [10]. The 
second, or definitive, wave results in the formation of the HSC compartment that will be 
the focus of this discussion. Definitive hematopoietic stem cells are capable of 
differentiating into all cell lineages found in the hematopoietic system, including 
lymphocytes (Figure 1.1). Early work suggested that these multipotent cells emerge from 
large embryonic arteries, including the umbilical artery, the vitelline artery, and the 
omphalomesenteric artery, as well as from a region of the developing embryo known as 
the aorta-gonad-mesonephros (AGM) [11-15]. Subsequent studies revealed that the 
placenta might also be a source of definitive HSCs [16, 17]. Among these putative sites 
of definitive HSC emergence, perhaps the best characterized is the AGM. Elegant 
microscopy analyses identified that ventral wall endothelial cells of the dorsal aorta, the 
major AGM blood vessel, undergo a morphologic change that results in the generation of 
hematopoietic stem and progenitor cells that bud into the aortic lumen  (Figure 1.2) [18]. 
The initiation of HSC specification from this specialized hemogenic endothelium was 
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shown to require Notch1 and Runx1 [19-21]. Since Notch1 deficiency results in a failure 
to up-regulate Runx1, and Runx1 over-expression rescues HSC specification defects in 
Notch1-deficient embryos, it seems that Notch signaling is a critical upstream regulator 
of definitive HSC emergence [19, 22]. These newly-specified HSCs then migrate through 
the vasculature to the fetal liver, the next major site of HSC development and expansion 
[23]. 
	  
Figure 1.1. The hierarchy of normal hematopoiesis. Long-term hematopoietic stem cells (LT-HSCs) are 
multipotent and capable of self-renewal. They differentiate into short-term hematopoietic stem cells (ST-
HSCs) and then multipotent progenitors (MPPs), which maintain multipotency, but are no longer capable 
of self-renewal. MPPs differentiate towards either the lymphoid or myeloid/erythroid lineages. Lymphoid-
primed multipotent progenitors (LMPPs) differentiate into either early T-lineage progenitors (ETPs) or 
common lymphoid progenitors (CLPs), before subsequent maturation into T cells or B cells, respectively. 
Common myeloid progenitors (CMPs) can differentiate into granulocyte-monocyte progenitors (GMPs) or 
megakaryocte-erythroid progenitors (MEPs). GMPs further differentiate into macrophages and 
granulocytes, while MEPs give rise to megakaryocytes and platelets or erythrocytes. 
Between embryonic days 12.5 and 16.5 (E12.5-E16.5), murine fetal liver HSCs 
expand nearly 40-fold, marking the most prolific expansion of HSCs during 
hematopoietic ontogeny [24]. Sustaining such an expansion requires vigorous cell cycle 
LT-HSC ST-HSC MPP
LMPP
CMP
ETP
CLP
GMP
MEP
T Cells
B Cells
Macrophages
Granulocytes
Megakaryocytes and Platelets
Erythrocytes
? ?
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activity and presumably a propensity towards symmetric, self-renewing divisions. The 
extrinsic signals that mediate this expansion remain largely unknown, but fetal HSCs 
cell-autonomously require the master transcriptional regulator Sox17 for proper 
development and function [25, 26].  Sox17 is robustly expressed in HSCs throughout fetal 
development and is rapidly extinguished around the time of birth, before becoming 
undetectable in adult bone marrow HSCs [25]. This pattern of expression is consistent 
with a significant role for Sox17 in fetal, but not adult HSC development. Fetal liver 
HSCs fail to expand in the absence of Sox17, and Sox17 over-expression confers fetal-
like self-renewal properties and cell cycle activity to adult hematopoietic progenitors [25, 
26]. This demonstrates that Sox17 is both necessary and partially sufficient to confer fetal 
HSC attributes to hematopoietic progenitors. These studies have led to Sox17 being 
termed a master regulator of fetal HSC development. 
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Figure 1.2. Definitive hematopoietic stem cell development. Hematopoietic stem cells emerge from 
hemogenic endothelium in the dorsal aorta between E9 and E10. These HSCs migrate to the fetal liver and 
robustly expand through self-renewing divisions between E11 and E18. Soon after birth, HSCs seed the 
bone marrow, and within 5 weeks, are predominantly found in the G0 phase of the cell cycle. At this point, 
most HSCs infrequently enter the cell cycle to maintain hematopoietic homeostasis during steady-state 
conditions. 
Fate-tracing studies revealed that fetal liver HSCs migrate to the bone marrow and 
persist to maintain long-term hematopoiesis throughout life [27, 28]. This HSC migration 
to the bone marrow marks the onset of a critical developmental transition known as the 
fetal to adult transition. The predominant feature of this transition is the robust exit of 
HSCs from the cell cycle within 4 weeks after birth [29]. During fetal life, up to 95% of 
HSCs are engaged in cell cycle activity to facilitate robust HSC expansion [29]. 
Conversely, after reaching the bone marrow, between 70% and 90% of HSCs exit the cell 
cycle and enter into a state of quiescence [29, 30]. Models of hematopoietic stress 
through chemical myeloablation indicate that BM HSCs can rapidly reenter the cell 
	   7	  
cycle, expand through self-renewing divisions, and differentiate in an attempt to 
reestablish hematopoietic homeostasis [30, 31]. This suggests that HSCs may sense the 
loss of downstream cell populations through an undefined mechanism. Such a mechanism 
could be triggered to replenish downstream cells lost to physiological cell turnover, or in 
stress situations such as major bleeding or infection. Interestingly, following the 
reestablishment of hematopoietic steady-state conditions, HSCs once again exit the cell 
cycle and become quiescent [30]. It is believed that this propensity towards quiescence is 
required for the ability of HSCs to self-renew throughout an organism’s lifetime, and is 
thus essential for HSC longevity. 
RESTRICTION OF HSC CELL CYCLE ENTRY: CELL-AUTONOMOUS AND NON-
AUTONOMOUS CUES 
 The finding that HSCs proliferate rapidly in the fetal liver, but then exit the cell 
cycle within a few weeks of seeding the bone marrow suggests that there may be factors 
in the bone marrow, so-called niche factors, required for the establishment and 
maintenance of quiescence. Indeed, several studies have demonstrated that specific bone 
marrow cytokines or factors may be required for efficient HSC cell cycle exit. 
 Thrombopoietin (TPO), a cytokine initially described for its role in promoting 
megakaryocye/platelet formation, is required for BM HSC quiescence and long-term self-
renewal [32, 33]. Human patients with mutations in c-mpl, the TPO receptor, initially 
present with thrombocytopenia, but eventually progress to pancytopenia [34]. This 
suggests roles for TPO beyond megakaryocyte development. Indeed, HSCs from mice 
that lack TPO expand normally in the fetal liver, but become depleted in the bone marrow 
within 1 year of birth [32]. Assessment of HSCs prior to depletion reveals that they fail to 
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enter quiescence upon reaching the bone marrow. This finding was linked to an inability 
to up-regulate expression of the cyclin-dependent kinase inhibitor (CDKI) p57 [32, 33]. 
p57 is critical to the maintenance of HSC quiescence [35, 36]. The transplantation of fetal 
liver and adult HSCs from Tpo-deficient donors revealed strikingly different outcomes 
[32]. If fetal liver HSCs from Tpo-deficient donors were transplanted into Tpo-sufficient 
recipients, they engrafted and maintained long-term hematopoiesis as well as wild-type 
donor HSCs. If HSCs from the bone marrow of young adult Tpo-deficient donors were 
transplanted, they showed significant functional defects. This suggested that the inability 
to establish quiescence had severely limited the self-renewal capacity of adult HSCs and 
that rapidly cycling fetal liver HSCs must have mechanisms to sustain enhanced self-
renewal that do not exist in adult BM HSCs. The nature of these mechanisms remains to 
be determined.  
 Angiopoietin-1 has similarly been linked to the maintenance of HSC quiescence 
and preservation of self-renewal activity [37]. Treatment of HSCs with angiopoietin-1 in 
vitro limited cell division, and resulted in preservation of self-renewal activity in 
hematopoietic transplantation assays after cell culture. Furthermore, Tie-2, the receptor of 
angiopoietin-1, was found to mark quiescent HSCs in vivo, suggesting that angiopoietin-
1/Tie-2 signaling could play a role in HSC quiescence in vivo. Direct testing of HSC cell 
cycle status or self-renewal activity in the absence of angiopoietin-1/Tie-2 signaling has 
not been reported, and is required to further examine the role that this pathway plays in 
the establishment and/or maintenance of HSC quiescence. 
 TGF-β signaling, like angiopoietin-1, limits HSC expansion in vitro and preserves 
self-renewal activity in transplantation assays [38]. The presence of TGF-β in culture 
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restricted HSCs from dividing, and this was found to facilitate stable long-term 
engraftment in transplant recipients, consistent with enhanced self-renewal. Reduced cell 
cycle activity was shown to be associated with increased expression of p57, again linking 
a cytokine to cell cycle regulation through this CDKI in the bone marrow [38, 39]. 
Further support for the role of TGF-β signaling in HSC self-renewal was provided by the 
finding that the loss of smad4, encoding a downstream transducer of TGF-β signaling, 
resulted in severe impairment of HSC function in transplantation experiments [40]. 
Together, these data supported a significant role for TGF-β in restricting HSC cell cycle 
entry and thus in preserving HSC self-renewal potential. 
 CXCL12, a chemokine expressed on perivascular stromal and endothelial cells in 
the bone marrow, is essential for HSC homing to the bone marrow, BM retention, and 
functional maintenance [41, 42]. CXCR4, the receptor for CXCL12 on HSCs, was shown 
to restrict HSC cell cycle entry and preserve quiescence [43]. CXCR4-deficient HSCs lost 
quiescence and showed increased cell cycle entry, as well as increased sensitivity to 
treatment with 5-fluoruracil treatment, an antimetabolite that kills dividing cells. 
Importantly, CXCR4-deficient HSCs also demonstrated reduced p57 gene expression.  
 The above studies indicate that CXCR4, Angiopoietin-1, TPO, and TGF-β all 
promote HSC quiescence in addition to expression of p57. Given that p57 is known to 
restrict cell cycle activity, it is attractive to postulate that p57 is a critical, cell-
autonomous factor in establishing and/or maintaining HSC quiescence. Direct evidence 
for this idea was provided in recent studies demonstrating that p57, along with the related 
CIP/KIP family member p27, cell-autonomously maintains HSC quiescence in vivo [35, 
36]. p57 played the dominant role in maintaining quiescence, though in the absence of 
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p57, p27 could partially compensate. In the absence of both p27 and p57, HSCs did not 
maintain quiescence and were eventually depleted. Transplantation assays revealed that 
this loss of quiescence significantly impaired self-renewal activity. These data reveal the 
essential role for CDKI expression in the maintenance of self-renewal, and support a link 
between niche signaling and the regulation of HSC quiescence.  
In addition to niche-mediated regulation of CDKI expression, HSCs actively 
restrict cell cycle entry in response to mitogenic signals from the phosphatidylinositol-3-
OH kinase (PI(3)K) pathway. PI(3)K signaling is critical to mediate the HSC response to 
pro-proliferative signals. Within this pathway, PTEN serves to attenuate PI(3)K 
signaling, thus limiting HSC proliferation. When PTEN was deleted, the HSC pool 
entered the cell cycle and transiently expanded before becoming profoundly depleted 
[44]. Additionally, Pten-/- HSCs had reduced self-renewal potential in bone marrow 
transplantation assays, suggesting that the increased responsiveness to proliferative 
stimuli was detrimental to self-renewal. Pten deficiency eventually resulted in the 
development of highly penetrant leukemia in mice. Prior to depletion, Pten-/- HSCs up-
regulated expression of the tumor suppressors Cdkn2a and p53, and progression to 
leukemia was associated with the loss of tumor suppressors through secondary mutations 
[45]. This suggested a model in which increased proliferative stress on HSCs was 
detrimental to self-renewal in normal hematopoiesis. At the same time, the accrual of 
secondary mutations in a cell population that had preexisting self-renewal potential 
provided a substrate for leukemogenesis.  
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REGULATION OF HSC SELF-RENEWAL 
 While extensive self-renewal is a fundamental feature of HSCs and is required for 
long-term function after transplantation, adult HSC self-renewal capacity is not 
unlimited. This phenomenon is clearly demonstrated in serial transplantation assays in 
which HSCs were successively transplanted 4-6 times, showing progressive functional 
decline [46, 47]. When genes required to promote HSC quiescence are mutated, HSCs 
often transiently expand but almost inevitably progress to functional decline [44, 48-51]. 
As indicated by the Pten-/- model, this limitation in self-renewal potential may in fact be 
adaptive to prevent leukemogenesis [25]. In this section, we discuss the diverse 
mechanisms through which HSCs promote and limit self-renewal activity. 
Telomeres and HSC self-renewal 
 Telomeres, the repetitive genomic sequences that cap linear chromosomes, have 
long been proposed to be a mitotic clock, limiting the lifespan of various proliferating 
cell populations [52]. With each round of replication, the inability to completely replicate 
the 3’ ends of DNA strands results in genomic erosion. If left unchecked, this erosion 
would eventually result in the loss of essential genetic material (the “end replication 
problem”). The telomere buffers DNA ends from such loss. Certain long-lived cell 
populations that maintain proliferative potential, including HSCs, express the 
ribonucleoprotein telomerase which can extend telomeres [53]. This activity is required 
for the maintenance of HSC self-renewal. 
 Since mice have long telomeres compared to humans, several generations of 
breeding are required before the effects of telomere shortening can be observed [54-56]. 
Initial studies reported that late generation telomerase-deficient mice had significantly 
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reduced hematopoietic output [56]. This reduced output was linked to decreased HSC 
function. When early generation telomerase-deficient HSCs were subjected to serial 
transplantation and thus forced to self-renew extensively, they exhibited severe functional 
deficits, consistent with an accelerated decline in self-renewal potential [57]. Analysis of 
telomere length in this system demonstrated that this self-renewal defect occurred 
concurrently with telomere shortening. These data suggest that in situations of severe 
hematopoietic stress, telomerase expression and the regulation of telomere length are 
absolutely required for the maintenance of HSC function. Interestingly, over-expression 
of telomerase did not by itself increase HSC longevity [58]. This suggests that while 
telomerase activity is necessary for prolonged HSC function, it is not sufficient to confer 
enhanced self-renewal capacity. 
 In addition to telomerase, telomeres require the shelterin protein complex for 
stability. This six-member protein complex physically protects telomeres from aberrant 
recognition by cellular DNA damage machinery (reviewed in detail in Chapter 4). 
Recent work indicates that individual components of the shelterin complex may be 
required for HSC maintenance [59, 60]. Due to differing functions among shelterin 
proteins in telomere protection, rigorous examination of HSC function in the absence of 
individual shelterin components must be evaluated to understand how shelterin 
contributes to HSC homeostasis. 
Epigenetic regulation of HSC self-renewal 
Many essential epigenetic regulators can be classified into one of two categories: 
regulators of DNA methylation and regulators of histone modifications. With regard to 
the former category, several genes have recently been identified that directly impact HSC 
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self-renewal. DNA methyltransferase 1 (DNMT1) was classified as a maintenance 
methyltransferase due to its function in reestablishing DNA methylation patterns 
reflecting those of a complimentary DNA strand after strand replication. Dnmt1 deletion 
resulted in defective self-renewal in adult HSCs [61]. Interestingly, Dnmt1 inactivation in 
primary mice did not cause major hematopoietic defects in primary mice. However, when 
wild-type HSCs were transplanted into unirradiated Dnmt1-/- mice, they stably engrafted 
the Dnmt1 hosts. This suggested that Dnmt1-deficient HSCs were not as stably associated 
with the niche as wild-type HSCs. Additionally, when Dnmt1-/- HSCs were transplanted 
into lethally irradiated recipients, they were functionally deficient, consistent with 
reduced self-renewal capacity. Since DNA methylation is associated with gene 
repression, it was predicted that Dnmt1 loss might lead to de-repression of multiple 
genetic targets. This was only partially true, as gene expression was both positively and 
negatively altered after Dntm1 deletion, indicating a complex function of DNMT1 in 
gene expression and self-renewal. 
DNMT3a and DNMT3b were both classified as de novo DNA methyltransferases, 
referring to the fact that they establish patterns of DNA methylation based on DNA 
sequence recognition and not on pre-existing complimentary strand methylation patterns. 
Initial studies demonstrated that HSCs deficient for both DNMT3a/b could not 
reconstitute lethally irradiated recipients, identifying a critical function for these 
methyltransferases in HSC self-renewal [62]. Deletion of Dnmt3a or Dnmt3b alone did 
not elicit a reported phenotype in these studies. However, recent studies reevaluating the 
function of DNMT3a in HSC function demonstrated that Dnmt3a-deficient HSCs 
actually had enhanced self-renewal, but impaired differentiation ability [63]. This finding 
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was reported following bone marrow transplantation experiments that showed HSC 
expansion out of proportion to their contribution to mature blood lineage reconstitution. 
In parallel, the authors observed de-repression of several genes associated with HSC 
identity and a paradoxical loss of expression of genes associated with lineage 
commitment. The mechanism by which Dnmt3a loss both positively and negatively 
affects gene expression is not clear. It is possible, however, that initial Dnmt3a deletion 
resulted in a de-repression of specific direct genetic targets, while the subsequent loss of 
lineage specification genes might have been a secondary consequence.  
Like DNA methylation, histone modification plays an essential role in the 
epigenetic regulation of gene expression. Many histone-modifying enzymes are classified 
into two diverse categories of epigenetic regulators: the Polycomb group (PcG) and the 
Trithorax group (TrG). The PcG class of epigenetic regulators is typically associated with 
gene repression. Within this group, the protein product of Bmi1, a ubiquitin ligase with 
histone 2a lysine 119 specificity, plays a critical role in adult HSC self-renewal [64]. 
Bmi1-deficient animals have normal fetal liver HSC development, but progress to 
hematopoietic failure with HSC depletion by young adulthood. Neither fetal nor adult 
HSCs are capable of long-term reconstitution in bone marrow transplantation assays, 
demonstrating a critical role for Bmi1 in HSC self-renewal. This reduced self-renewal 
potential is partially explained by cell-autonomous de-repression of Cdkn2a and Cdkn2d, 
and premature HSC senescence [64]. Additionally, cell non-autonomous effects 
attributed to Bmi1 deficiency in the BM niche play a significant role in HSC functional 
decline independent of Cdkn2a and Cdkn2d [65]. Thus, Bmi1 has complex cell-
autonomous and non-autonomous functions in the maintenance of HSC self-renewal. 
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Ezh1, a PcG member whose protein product methylates histone 3 lysine 27 
residues, has similarly been linked to HSC self-renewal [66]. As with Bmi1 loss, Ezh1 
loss prevented stable long-term reconstitution in transplantation assays. In this model, 
self-renewal defects were rescued by Cdkn2a deletion, again suggesting that premature 
senescence was linked to defective self-renewal. Thus, it seems that PcG members share 
a common role in suppressing cellular senescence in HSCs, and that this function is 
required for the long-term maintenance of HSC self-renewal potential. 
Whereas PcG members are associated with target gene repression, TrG members 
are required for the activation or maintenance of gene expression. The role of the TrG in 
mammalian hematopoiesis is reviewed extensively in Chapter 2. Briefly, Mll1 is a 
histone 3 lysine 4-specific methyltransferase required for target gene expression. Loss of 
Mll1 results in aberrant HSC cell cycle entry and defective self-renewal in bone marrow 
transplantation assays [67, 68]. Unlike Ezh1 or Bmi1 deficiency, which caused self-
renewal defects due to premature senescence, self-renewal defects due to Mll1 deletion 
correlated with excessive cell cycle entry. This phenomenon is a poorly defined concept 
known as HSC exhaustion that broadly describes reduced HSC function and self-renewal 
defects that follow a period of excessive HSC cell cycle activity. The molecular 
mechanisms that contribute to exhaustion are unclear, though they are believed to relate 
to increased metabolic stress and DNA damage that occurs due to aberrant cell cycle 
entry, similar to the prevailing model to explain HSC defects in the absence of PTEN. 
Mll5 was defined as a TrG member due to homology to Mll1, though SET domain 
functionality has not been identified. Mll5 deficiency increased HSC cell cycle entry, 
though not as robustly as in Mll1-deficient HSCs [69-71]. In addition to enhanced cell 
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cycle entry, Mll5-deficient HSCs failed to support long-term hematopoietic reconstitution 
in transplantation assays, again indicating a functional role for Mll5 in HSC self-renewal 
[70, 71]. Our current understanding of the mechanisms by which Mll1 and Mll5 impact 
self-renewal is reviewed in Chapter 2. 
Taken together, these data indicate that epigenetic regulation plays an essential, 
diverse role in the maintenance of HSC self-renewal. Though effects on self-renewal 
have been identified with respect to Dnmt1, Dnmt3a, Bmi1, Ezh1, Mll1, and Mll5, the 
molecular mechanisms by which each of these genes contributes to self-renewal remain 
poorly defined. Furthermore, the potential interactions between different epigenetic 
regulators in controlling HSC function have not been explored. Such studies will provide 
insight into the complex means through which epigenetic modifiers affect HSC self-
renewal. 
ROS, Metabolism, and HSC Self-Renewal 
Reactive oxygen species (ROS), a byproduct of oxidative metabolism, critically 
limit HSC function (reviewed in [72]). It is thought that to control exposure to oxygen 
toxicity, quiescent HSCs localize to a hypoxic niche [73]. Within this niche, HSCs further 
suppress ROS accumulation through increased expression of FoxO family members and 
the DNA damage response protein ATM (encoded by Ataxia telangectasia mutated) [74, 
75]. Reduced ROS suppression due to the loss of either of these key factors results in 
compromised HSC self-renewal. Similarly, an inability to mount a Hif-1α-dependent 
oxidative stress response results in HSC depletion, aberrant cell cycle entry, and reduced 
self-renewal potential [76]. These data support the concept that HSCs must efficiently 
limit ROS exposure to maintain self-renewal and normal functionality.  
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Consistent with a preference for hypoxic conditions, HSCs require efficient 
gycolysis for long-term maintenance [77]. HSCs in which Pyruvate dehydrogenase 
kinase 1 and 2 were deleted to inhibit glycolysis aberrantly entered the cell cycle, became 
depleted, and lost self-renewal capacity in transplantation assays. Despite the HSC 
preference for low oxygen conditions and glycolysis, recent studies have sought to 
evaluate the role of mitochondria and oxidative metabolism in HSC self-renewal. 
PTPMT1 is a mitochondrial phosphatase with an unclear physiological function, but that 
is required for oxidative metabolism. Supporting the notion that HSCs are more sensitive 
to disruption in glycolysis than mitochondrial aerobic respiration, inhibiting 
mitochondrial function through PTPMT1 deletion did not limit HSC self-renewal [78]. 
Interestingly, PTMPT1-deficient HSCs failed to differentiate into mature lineages. This is 
hypothesized to be because lineage-committed progenitors require aerobic metabolism, 
which was perturbed by PTPMT1 loss. Thus, whereas HSCs are able to survive and self-
renew in the absence of PTPMT1, downstream progenitors dependent on efficient aerobic 
metabolism are sensitive to this loss.  
 While work with PTMPT1 suggested that HSC self-renewal was independent of 
oxidative metabolism, studies focused on Lkb1 revealed that mitochondrial function 
might still be essential for HSC maintenance. Lkb1 was initially identified as a positive 
regulator of AMPK involved in reducing cellular energy expenditure by limiting 
macromolecule synthesis. While the significance of Lkb1 regulation of AMPK in HSCs 
is unclear, a critical role in HSC mitochondrial function has been elucidated [79-81]. 
Following Lkb1 deletion, HSCs lost quiescence and transiently expanded before being 
rapidly depleted [79, 81]. Lkb1-/- HSCs demonstrated profound self-renewal limitations in 
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bone marrow transplantation [79-81]. Analysis of the defective Lkb1-/- HSCs revealed 
reduced mitochondrial mass, mitochondrial membrane potential, and ATP synthesis, 
suggesting that perturbed mitochondrial function contributed to the observed HSC 
defects. These data suggest that HSCs require a low, basal level of oxidative metabolism. 
According to this hypothesis, PTMPT1 loss, while promoting reduced respiration, did not 
reduce metabolic output below this level. Lkb1 loss, on the other hand, limited 
mitochondrial function so that metabolic output was below even this low threshold, 
resulting in HSC defects. Although clarification is needed, these findings illustrate the 
need to further explore the metabolic regulation of HSC function. 
Inflammation and HSC self-renewal 
Recent studies demonstrate that HSCs can enter the cell cycle and robustly 
expand in response to bacterial infection [82]. This is hypothesized to facilitate the 
expansion of downstream cell populations that are required to combat infection. While 
this transient HSC expansion is adaptive, several lines of evidence suggest that chronic 
infection has detrimental effects on HSCs. 
Interferons are cytokines that play critical roles in the immune response to various 
forms of infection. Acute exposure to interferon-α (IFNα), a type I interferon, resulted in 
increased HSC proliferation, but did not impair HSC function [83]. When HSCs were 
subjected to chronic IFNα exposure, however, self-renewal activity was severely 
impaired in transplantation assays, suggestive of HSC exhaustion. Similarly, when HSCs 
were chronically exposed to interferon-γ (IFNγ), a type II interferon, during chronic 
infection with Mycobacterium avium, increased cell cycle entry was observed followed 
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by impaired self-renewal in transplantation assays [84]. Collectively, these data 
demonstrate that while an adaptive expansion of HSCs might occur during infection, 
chronic infection and associated HSC proliferation impair long-term self-renewal. 
Additional studies demonstrate that HSCs have evolved intrinsic mechanisms that 
limit their response to infection. Deletion of the negative regulator of interferon signaling 
Irf2 resulted in an IFNα-dependent HSC depletion [85]. Loss of this negative regulator 
exacerbated HSC exhaustion following chronic IFNα exposure. Similarly, loss of Igrm1, 
another negative regulator of interferon signaling, resulted in defective HSC self-renewal 
in an interferon-dependent fashion [86]. These mechanisms dampen HSC responsiveness 
to infections and are required to preserve HSC self-renewal in pathological conditions.   
SUMMARY 
 In this report we describe two novel regulators of HSC maintenance and self-
renewal. Chapter 3 describes Absent, small, or homeotic 1-like (Ash1l), a member of the 
TrG, as being an essential regulator of HSC function. We discovered that Ash1l plays a 
critical role in the establishment of HSC quiescence in the bone marrow, at least in part 
through regulation of CDKI expression. Loss of quiescence in this model results in the 
absence of detectable long-term self-renewal activity in transplantation assays. We 
further demonstrate that Ash1l functionally cooperates with Mll1 to maintain 
hematopoietic homeostasis, thus representing the first identification of in vivo 
cooperativity between TrG members in mammalian developmental biology. Surprisingly, 
despite a severely compromised HSC compartment, Ash1l-deficient mice do not succumb 
to hematopoietic failure. We observe increased cell cycle activity in downstream 
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progenitors, suggesting that they may have sufficient self-renewal activity to maintain 
hematopoiesis in the absence of HSCs.  
Chapter 5 describes that Tpp1 (encoded by Acd), a member of the shelterin 
complex of telomere-protecting proteins, is also critical for HSC self-renewal. Acd loss 
results in acute HSC depletion and an inability for HSCs to self-renew in transplantation 
assays. This functional decline is preceded by p53 activation and cell cycle arrest, though 
unlike in other stem cell compartments, genetic p53 ablation does not rescue HSC 
function. Acd deficiency thus provides a novel model of acute telomere deprotection in 
stem cells and implicates Tpp1 as an essential factor in the preservation of HSC self-
renewal potential. These findings contrast previous studies that described a gradual 
progression to hematopoietic failure following shelterin loss. Our data suggest that acute 
stem and progenitor dysfunction may underlie hematopoietic failure and thus should be 
rigorously evaluated in other models of acute telomere deprotection. 
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CHAPTER 2.  THE TRITHORAX GROUP: A CONSERVED 
CLASS OF EPIGENETIC REGULATORS WITH ESSENTIAL 
FUNCTIONS IN HEMATOPOIESIS 
INTRODUCTION  
The function of the trithorax group (TrG) of epigenetic regulators has been of 
particular interest since the discovery that Mixed-lineage leukemia-1 (Mll1) is a frequent 
fusion partner in a subset of pediatric and adult leukemias [87-89]. This gene is the 
mammalian homolog of Drosophila trithorax, a TrG member with a well-characterized 
role in Drosophila body patterning. Understanding the conserved mechanisms through 
which TrG members regulate developmental body patterning has provided important 
insight into how TrG members regulate normal and malignant hematopoiesis.   
THE TRITHORAX GROUP (TRG) IN DROSOPHILA BODY PATTERNING 
 Drosophila anterior-posterior body segmentation requires precise, ordered gene 
expression at loci encoded within the antennapedia and bithorax complexes (reviewed in 
[90]). Together, these clusters encode 8 homeobox (hox) genes that are expressed along 
the anterior-posterior body axis in the order in which they are encoded within the cluster. 
Transcription is initiated from these loci based on a gradient of maternally encoded 
transcription factors. After this initiation, Polycomb group (PcG) and Trithorax group 
(TrG) proteins are required for the maintenance of hox expression patterns, and thus for 
proper body segmentation as the fly embryo expands. TrG and PcG members achieve this 
activity through positive and negative regulation of hox targets, respectively. 
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Inappropriate hox gene expression during development is sufficient to transform one 
body segment into another reflective of the altered hox expression (“homeotic 
transformation”). 
 In flies, members of the TrG were defined by three main characteristics: 1. 
Mutations in TrG members result in homeotic transformations consistent with hox loss-
of-function; 2. Combined heterozygous mutations of different group members reveal that 
they serve as dominant enhancers of one another, increasing the penetrance of homeotic 
phenotypes; 3. Mutations in TrG members suppressed PcG loss-of-function phenotypes 
(which reflected hox gain-of-function mutations) [91]. trithorax, the archetypal TrG 
member, was originally described in flies with homeotic transformations consistent with 
loss of bithorax cluster expression [92, 93]. This identification came from body 
patterning screens in which mutations were identified that did not map to a known hox 
locus. Furthermore, mutant phenotypes were consistent with reduced expression of 
several hox loci within the bithorax cluster, suggestive of the loss of an upstream 
regulator. Later work revealed that in addition to causing reduced bithorax expression, 
trithorax loss-of-function mutations decreased antennapedia complex expression and 
suppressed the effects of polycomb mutations [94]. At the time, it was clear that 
polycomb acted as a negative regulator of the bithorax cluster, and together, these data 
demonstrated that trithorax was a positive regulator of Drosophila hox genes.   
 Two additional members of the TrG were identified in studies pursuing a 
Drosophila mutant phenotype characterized by prominent imaginal disc defects [95]. 
Imaginal discs are the precursors of Drosophila appendages and, as for body 
segmentation, require defined hox expression patterns for proper specification. Each set 
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of appendages (i.e. the antennae, wings, legs, eyes) develops from a pair of imaginal disc 
precursors. A series of imaginal disc mutants in which the discs were either absent, small, 
or homeotically transformed into a different disc (i.e. antenna disc to leg disc resulting in 
leg growth where an antenna should be) were initially described in 1971 [95]. Over a 
decade later, two genes, termed absent, small, or homeotic 1 and 2 (ash1 and ash2) were 
shown to be the causal loci accounting for these mutant phenotypes [96]. 
 The identification of ash1, ash2, and trithorax resulted in the description of the 
Trithorax group (TrG) [97]. Each member of this group promotes expression of hox 
cluster genes. The combined heterozygosity for loss-of-function mutations in any pair of 
these genes results in enhancement of homeotic phenotypes. Phenotypes associated with 
polycomb loss-of-function mutations (consistent with hox gain-of-function) are 
suppressed by mutation in any of these TrG members. Together, this report identified the 
TrG as a group of functionally related proteins that promoted gene expression, and acted 
in opposition to PcG members to preserve proper body patterning.  
 A subsequent screen for suppressors of polycomb phenotypes revealed that 
brahma also met the criteria for inclusion in the TrG [98]. As was true for other TrG 
members, brahma loss-of-function resulted in phenotypes consistent with loss of 
antennapedia and bithorax complex expression. Additionally, brahma mutations 
enhanced phenotypes associated with trithorax and ash1 mutations, demonstrating a 
functional interaction between brahma and trithorax and therein fulfilling the criteria for 
TrG inclusion [98, 99]. 
 While TrG members are functionally related in promoting hox gene transcription, 
the mechanisms through which they do so are diverse. ash1 and trithorax both encode 
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large proteins that contain a SET domain [100, 101]. This domain, named for its presence 
in the su(var)3-9, e(z), and trithorax proteins, confers histone methyltransferase activity 
to ash1 and trithorax (reviewed in [102]). ash2 does not encode a SET domain, though it 
may enhance histone methyltransferase activity of other SET domain-containing TrG 
members [103]. brahma is a homolog of a component of the yeast SWI/SNF complex 
[98]. This complex hydrolyzes ATP to physically move histones, and thus influences 
transcription through alterations in chromatin structure [104, 105]. These proteins are 
representative of the diverse mechanisms through which TrG members, of which 13 have 
been identified in total, promote gene expression from target loci (for additional TrG 
members, see [106]). While diverse biochemical functions have been identified for TrG 
members, the role that these functions may play in cooperativity between TrG members 
has not been identified. 
THE TRG IN MAMMALIAN BODY PATTERNING 
 As in Drosophila, mammalian body patterning requires proper Hox gene 
expression. Whereas there are 8 hox genes in Drosophila, 39 Hox loci have been 
identified in mammals (reviewed in [107] and [108]). Mutations in multiple Hox loci 
cause homeotic transformations of vertebral segments [109-111]. This demonstrates that 
Hox gene expression is required for anterior-posterior segmentation in mammals, and 
suggests that similar regulatory mechanisms may exist between mammals and 
Drosophila. However, while significant work has been done in describing the roles of 
Drosophila TrG members as upstream regulators of body patterning, relatively little work 
has been done in the mammalian system. Here, we review our current understanding of 
how mammalian TrG members regulate the establishment of the body plan. 
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Mll1 
 The mammalian homolog of trithorax, Mixed-lineage leukemia 1 (Mll1), was 
originally identified for its oncogenic role in pediatric leukemias (discussed below). Mll1 
bares significant amino acid sequence homology to Set1 family histone 
methyltransferases, a class of lysine modifying enzymes that promote gene expression 
through histone 3 lysine 4 methylation [112-114]. Comparison of protein structural 
domains between Mll1 and Setd1a, a classical Set1 family member, demonstrates that 
both proteins possess a C-terminal SET domain followed by a post-SET domain (Figure 
2.1). This C-terminal SET domain is characteristic of SET1-like proteins. Mll1 histone 
methyltransferase activity requires interactions with the cofactors WDR5, Ash2l, and 
RbBP5 for catalysis and with menin for binding to relevant loci [115-119]. Additional 
specificity in Mll1 targeting is provided by its interaction with the PAF transcriptional 
elongation complex. This interaction is required for Mll1 targeting to a subset of Hox 
loci, and suggests an additional role for Mll1 in regulating transcriptional elongation at 
individual target genes [120, 121]. In addition to cofactor-mediated targeting, Mll1 itself 
contains several domains that promote interactions with DNA and chromatin. The N-
terminus contains 3 closely-spaced AT hooks, which are known to facilitate binding with 
the minor groove of DNA [122]. These AT hooks are followed by a series of 3 PHD 
fingers and a bromodomain, which bind methylated and acetylated lysine residues, 
respectively [123, 124]. Mll1 therefore uses a combination of protein-protein, protein-
DNA, and protein-chromatin interactions for specific targeting to gene loci.  
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Figure 2.1. Structural organization of selected murine SET domain-containing proteins. Setd1a and 
Mll1 show conserved C-terminal SET domain localization characteristic of SET1 family histone 
methyltransferases. Setd2 and Ash1l show internal SET domains characteristic of SET2 family histone 
methyltransferases. Mll5 does not clearly fit a SET1 or SET2 family classification due to its N-terminal 
SET domain. All images are drawn to scale and conserved domains were identified using UniProt. 
Initial characterization of mice heterozygous for an Mll1 null allele described 
prominent homeotic transformations along the vertebral column consistent with reduced 
Hox gene expression [125]. Further analysis revealed that Hox boundaries were shifted in 
heterozygous animals, while animals with a complete loss of Mll1 expression eventually 
lost Hox expression and died in utero. These data established that Mll1, like its homolog, 
is required for proper Hox expression and subsequent body segmentation in mammals. 
 Developmental Hox gene defects and consequent homeotic transformations have 
been linked to the catalytic activity of the Mll1 SET domain [126]. Ablation of the SET 
domain recapitulated many of the axial skeletal phenotypes and Hox expression 
abnormalities reported in Mll1 loss-of-function studies. This work established that Mll1 
histone methyltransferase activity is required for normal Hox gene expression. Of note, 
SET domain deletion did not cause embryonic lethality, as was reported with the Mll1 
null allele, suggesting that Mll1 may have additional functions in development beyond 
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SET domain-mediated catalysis [125, 126].  While SET-independent functions remain to 
be explored, the catalytically inactive Mll1 revealed that SET domain activity was 
specific to methylation at histone 3 lysine 4 (H3K4) residues [126]. Subsequent analyses 
showed that Mll1 is predominantly responsible for H3K4 di- and trimethylation, a histone 
mark associated with positive regulation of gene expression [115, 127]. Together, these 
data indicate that Mll1 directly regulates transcriptional output from target genes, 
including those of the Hox cluster. 
 Further studies demonstrated that Mll1 is required for the maintenance of Hox 
gene expression in developing mouse embryos [128]. While Mll1-deficient fetuses 
normally expressed Hox genes at early developmental time points, Hox expression was 
eventually lost, suggesting that Mll1 is not required for initiating Hox gene expression, 
but rather for maintaining expression as tissues expand. This reflects a conserved 
functional paradigm between Drosophila and mammals in which Mll1 is required to 
preserve cellular memory of Hox expression patterns during body segmentation. 
 In addition to positively regulating Hox gene expression, Mll1 antagonizes the 
function of the PcG member Bmi1 [129]. Combined deficiencies in Mll1 and Bmi1 
suppressed homeotic transformations of the axial skeleton. Studies of gene expression 
differences in MEFs derived from Mll1- and Bmi1-deficient embryos identified 
complementary patterns of Hox gene expression where genes that appeared to be de-
repressed in the absence of Bmi1 failed to be expressed when Mll1 levels were reduced. 
This suggests the existence of a highly conserved crosstalk between mammalian TrG and 
PcG proteins in developmental body patterning and Hox gene expression. 
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Ash1l  
Beyond studies of Mll1 in body patterning, little work has been done 
characterizing the role that other TrG homologs might play in development. Recent 
evidence suggests that Ash1-like (Ash1l), the homolog of fly ash1, has a significant role 
in axial skeletal development (Camper et al., personal communication). Mice 
homozygous for a “gene trap” loss-of-function allele that results in profound 
hypomorphism for Ash1l (described in Chapter 3) display prominent rib patterning 
defects, predominantly in the form of extra thoracic ribs with abnormal sternal 
attachments. This finding was reminiscent of phenotypes ascribed to Hox loss-of-function 
and suggests that Ash1l plays a conserved function in mammalian body patterning, 
though additional studies will be required to identify the precise molecular targets 
involved in axial skeletal development. 
By analogy to Mll1, it is tempting to speculate that Ash1l functions in positive 
regulation of Hox expression through SET domain catalysis. Several independent groups 
have associated Ash1l SET domain activity with H3K4, H3K9, H3K36, and H4K20 
methylation [130-133]. Recent studies using rigorous biochemistry and crystallography 
indicated that H3K36 dimethylation is the most likely specificity for the Ash1l SET 
domain [134, 135]. Supporting this finding, amino acid sequence analysis reveals 
significant homology to Set2 proteins, a family of histone 3 lysine 36-specific 
methyltransferases [133, 136]. Histone 3 lysine 36 methylation is a cotranscriptional 
histone modification that facilitates effective transcription through promoting efficient 
mRNA splicing and limiting aberrant initiation from cryptic promoters [137-139]. As is 
characteristic of Set2 family members, the Ash1l SET domain is internal to the protein, as 
opposed to being at the C-terminus like Mll1 (Figure 2.1). Amino acid sequence analysis 
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reveals an associated-with SET (AWS) domain upstream of the Ash1l SET domain; this 
feature is shared among Set2 family members. Ash1l also includes 3 AT hooks, a 
bromodomain, and a PHD finger, thus promoting DNA, acetylated lysine, and methylated 
lysine binding, respectively. Additional cofactors required for Ash1l targeting to gene 
loci have not yet been identified. Moreover, direct catalytic function of Ash1l at target 
loci has not been described in vivo. Thus, while it seems that Ash1l directly binds several 
Hox loci in cultured cells, the physiological significance of this binding is unknown 
[130]. 
THE TRG AND HEMATOPOIESIS 
 As implied by the name, Mll1 (in humans MLL1) was originally identified in the 
context of hematopoiesis, and specifically in leukemia. Work from several groups 
demonstrated that the MLL1 locus was involved in chromosomal translocations at the 
11q23 locus in pediatric and adult leukemia patients with an increased incidence in 
infants and patients with secondary leukemias after exposure to topoisomerase II 
inhibitors [87-89]. Understanding the mechanistic implications of this translocation is 
significant, as patients with MLL1 fusions have a particularly poor prognosis. We now 
know that there are more than 60 gene fusions involving MLL1 [140].  While these 
fusions are diverse and often result in the loss of the MLL1 C-terminal SET domain, they 
uniformly cause increased Hox gene expression [141, 142]. These findings suggest a 
significant role for both Hox genes and MLL1 in hematopoiesis.  
 Initial studies focused on identifying a potential role for Mll1 in hematopoiesis 
demonstrated critical functions in fetal hematopoietic stem cell development. The 
assessment of fetal liver hematopoiesis in Mll1-deficient mice revealed reduced 
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cellularity, though mutlilineage differentiation appeared intact [143]. This was initially 
attributed to proper HSC specification, but subsequent failure in HSC fetal liver 
expansion. Later studies identified that Mll1-deficient HSCs were already significantly 
reduced in the AGM region, suggesting a role for Mll1 in the emergence of definitive 
hematopoiesis [144]. 
 Studies using embryoid bodies derived from Mll1-deficient embryonic stem cells 
revealed the role for Mll1 regulation of Hox genes in hematopoietic development [145]. 
Analysis of Hox gene expression over the course of hematopoietic specification from 
embryoid bodies revealed that several genes, including Hoxa7, Hoxa9, and Hoxa10 were 
significantly upregulated during this process. Importantly, these genes have also been 
identified as targets of MLL1 leukemogenic fusions [141, 142, 146]. Mll1-deficient 
embryoid bodies failed to upregulate expression of these Hox genes, and hematopoietic 
progenitors derived from these embryoid bodies failed to expand [145]. This provided the 
first evidence that a Mll1-dependent Hox program may be required for hematopoietic 
development, though this evidence is indirect, as a failure to specify normal 
hematopoietic progenitors for other reasons could result in reduced Hox expression. 
 Mll1-deficient embryos had significant developmental defects outside of 
hematopoiesis, thus complicating the in vivo understanding of Mll1 function. Though the 
embryoid body studies strongly suggested that Mll1 drives Hox expression, additional 
genetic tools were required to test the cell-autonomous function of Mll1 in HSC 
development and function. Such tools were provided when two groups independently 
developed Mll1 conditional alleles [67, 68]. Conditional inactivation of Mll1 revealed 
that Mll1 was required for the maintenance of HSC self-renewal [67, 68]. Transplantation 
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assays demonstrated that Mll1 deficiency was incompatible with long-term reconstitution, 
the gold standard for testing HSC self-renewal. Furthermore, Mll1 deficiency resulted in 
the loss of HSC quiescence prior to depletion, suggesting that Mll1-deficient HSCs 
aberrantly entered the cell cycle [67]. Mll1-deficient hematopoietic progenitors lost 
expression of Hoxa7, Hoxa9, and Hoxa10 prior to the observed self-renewal defects. 
These data expanded our understanding of the function of Mll1 in hematopoiesis and 
identified that Mll1 function was critical for HSC maintenance and self-renewal. 
 Intriguingly, the two studies identifying profound HSC defects in the absence of 
Mll1 reported different phenotypic severities, though both reports described comparable 
self-renewal defects upon transplantation. Jude and colleagues described a rapid 
progression to HSC depletion and bone marrow failure shortly after induction of Mll1 
excision [67]. This latter finding was linked to additional roles of Mll1 in myeloid and 
lymphoid progenitor function. McMahon and colleagues reported that they could stably 
excise Mll1 in fetuses and that this did not cause a defect in postnatal hematopoiesis in 
the absence of transplantation [68]. This study did identify reduced myeloid progenitor 
function in methylcellulose cultures, indicative of a role for Mll1 downstream of HSCs. 
Thus, the predominant difference between these two studies was the extent of HSC 
depletion in primary mice and progression to bone marrow failure. The reason for this 
difference is unknown, though perhaps alternative means of conditional allele generation 
or different Cre induction strategies between the groups could account for these findings. 
 The tumor suppressor menin was demonstrated to be required for both 
endogenous Mll1 and Mll1 fusion protein targeting to Hox loci [118, 147-149]. This 
function is dependent on the link that menin provides between Mll1 and LEDGF as an 
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adaptor protein during Mll1 recruitment to target loci [117]. Thus, loss of Men1 
(encoding menin) is predicted to reflect Mll1 loss-of-function in hematopoietic tissues. 
Analysis of Men1 deficiency revealed that, as Mll1, menin is required for HSC self-
renewal [150]. Similar to the phenotype reported by McMahon and colleagues, 
Men1deficiency resulted in HSC functional defects in transplantation assays, but not in 
primary mice. Hematopoietic progenitors had reduced expression of Hoxa9 and Hoxa10, 
reminiscent of gene expression changes observed in Mll1 deficiency. These data further 
support a critical role for Mll1 in HSC self-renewal, and thus in HSC function.  
 The finding that Mll1-driven leukemogenesis correlates with increased Hox 
expression and that HSC self-renewal defects in the absence of Mll1 were characterized 
by loss of Hox expression suggested that Hox genes might play critical roles in self-
renewal. Indeed, Hoxa9 deficiency results in impaired hematopoietic recovery following 
irradiation, which could reflect underlying HSC self-renewal defects [151]. Defective 
self-renewal was confirmed in transplantation assays, identifying Hoxa9 as a key 
regulator of HSC self-renewal. However, this phenotype is not as severe as that which is 
observed when Mll1 is lost, consistent with the idea that Mll1 is an upstream regulator of 
Hoxa9 and additional targets. Further supporting a role for Hoxa9 in self-renewal, Hoxa9 
over-expression was capable of imparting increased self-renewal properties on 
hematopoietic progenitors, though generation of transplantable leukemias required co-
expression of the Hox co-factor Meis1 [146, 152, 153].  
 The TrG member Mll5 is a SET domain-containing protein with limited 
homology to Mll1 that includes a N-terminal SET domain lacking an identified function 
(Figure 2.1).  Mll5 has also been implicated in regulating HSC function [69-71]. 
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Hematopoietic progenitors lacking Mll5 entered the cell cycle at an increased rate, 
suggestive of a loss of quiescence [69, 71]. Hematopoietic stress induced by sublethal 
irradiation or 5-fluorouracil injection resulted in the progression to bone marrow failure 
in Mll5-deficient mice [70, 71]. While increased cell cycle activity can contribute to 
heightened sensitivity to either of these treatments, reduced self-renewal can also limit 
the expansion of the stem cell pool that is required for recovery. Subsequent testing of 
self-renewal in transplantation demonstrated severe HSC functional impairment in Mll5 
knockout animals [70, 71]. Further analysis of hematopoietic progenitors revealed that 
Mll5 deficiency resulted in reduced expression of Hoxa7 and Hoxa9 [71]. Mll5, like 
Mll1, is therefore required for HSC self-renewal. 
 Beyond this body of work identifying roles for Mll1 and Mll5 in HSC self-
renewal and hematopoietic homeostasis, little is known about the function of additional 
TrG members in mammalian hematopoiesis. Furthermore, while Mll1 and Mll5 seem to 
regulate partially overlapping genetic targets, cooperativity between these and any other 
TrG members in hematopoiesis has not been evaluated. Thus, while focus has been 
placed on Mll1 because of its role in human malignancy, much work remains in 
understanding the role that TrG proteins may have in HSC function and hematopoietic 
homeostasis. 
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CHAPTER 3.  THE TRITHORAX GROUP MEMBER ASH1L 
FUNCTIONALLY COOPERATES WITH MLL1 TO REGULATE 
HEMATOPOIETIC STEM CELL QUIESCENCE AND SELF-
RENEWAL 
* 
ABSTRACT 	   Hematopoietic homeostasis requires that rare hematopoietic stem cells (HSCs) 
balance the processes of differentiation and self-renewal to sustain long-term 
hematopoietic output. To preserve long-term function, HSCs largely remain outside of 
the cell cycle in a quiescent state that limits their exposure to replicative stress. In this 
study, we identify the Trithorax group (TrG) member Absent, small, or homeotic 1-like 
(Ash1l) as being required for the induction and maintenance of this quiescent state during 
the neonatal period. In the absence of Ash1l, HSCs actively cycle and eventually become 
profoundly depleted by young adulthood. This inability to achieve quiescence correlates 
with reduced expression of p27 and p57, two cyclin-dependent kinase inhibitors required 
for the maintenance of quiescence. Intriguingly, bone marrow transplantation assays fail 
to identify HSC function in the fetal or adult Ash1-deficient bone marrow. Despite this 
finding, Ash1l-deficient mice do not progress to hematopoietic failure, suggesting that 
few remaining LT-HSCs or downstream progenitors are sufficient to maintain survival 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
* Material in this chapter is modified from: 
Jones, M., Brinkmeier, M. L., Weinberg, D. N., Schira, J., Friedman, A., Camper, S. A., 
and Maillard, I., The Trithorax group member Ash1l functionally cooperates with Mll1 to 
regulate hematopoietic stem cell quiescence and self-renewal. Manuscript in preparation.   
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for more than 6 months in this model. Additionally, we demonstrate that this HSC 
functional deficit results in niche availability such that Ash1l-deficient mice can be 
engrafted with wild-type HSCs in the absence of irradiation. Ash1l functionally 
cooperates with the TrG member Mll1 to promote hematopoietic stem cell function and 
homeostasis, identifying conserved cooperativity between TrG members for the first time 
in mammals. These data demonstrate that Ash1l plays an essential role in the maintenance 
and function of HSCs.   
INTRODUCTION 
Sustained hematopoiesis requires that long-term hematopoietic stem cells (LT-
HSCs) balance the processes of self-renewal and differentiation. To maintain self-
renewal, LT-HSCs must primarily remain outside of the cell cycle, or in a quiescent state. 
Establishment of quiescence occurs within 4 weeks of homing to the bone marrow, 
marking a transition from robust cell cycle activity in the fetal liver to quiescence in the 
adult bone marrow [29]. The failure to establish or maintain quiescence is often linked to 
LT-HSC depletion, increased sensitivity to myelosuppression, and reduced engraftment 
in bone marrow transplantation assays [29, 32, 36, 154]. Thus, understanding the 
mechanisms through which LT-HSCs establish and maintain quiescence is critical to 
understanding self-renewal and long-term hematopoietic output from these rare cells. 
The Trithorax group (TrG) is a diverse class of epigenetic regulators that was 
originally identified as being required for Drosophila body patterning (reviewed in 
[106]). Collectively, TrG proteins maintain proper expression of the antennapedia and 
bithorax complexes to affect proper segmentation during embryogenesis (reviewed in 
[90]). In Drosophila, individual TrG members function non-redundantly to promote gene 
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expression from these homeobox (hox) loci such that combined heterozygous mutations 
of TrG members function as dominant enhancers of one another [97, 99]. TrG members 
have a conserved function in developmental body segmentation in mammals. Mice 
deficient for Mixed-lineage leukemia 1 (Mll1), the mammalian homolog of trithorax, 
have disrupted body segmentation due to a failure of the maintenance of Hox gene 
expression [125]. Additionally, mice deficient for the TrG member Absent, small, or 
homeotic 1-like (Ash1l), the mammalian homolog of Drosophila ash1, have disrupted 
body patterning as evidenced by axial skeleton abnormalities attributable to defective 
Hox gene expression (Brinkmeier and Camper, personal communication). While these 
data suggest that TrG members may share a conserved, non-redundant role in mammalian 
development, this concept has not yet been evaluated. 
Past work demonstrated a critical role for Mll1 in both normal and malignant 
hematopoiesis. Mll1 was originally identified as a frequent partner in genetic fusions 
driving human leukemias in both infants and adults [87-89]. These leukemias 
demonstrate a characteristic aberrant upregulation of Hox gene expression [141, 142]. 
Additional work demonstrated that Mll1 was required for the maintenance of normal 
hematopoietic stem cells (HSCs) through a critical function in the preservation of HSC 
self-renewal [67, 68]. Mll1-deficient mice had reduced Hox gene expression in HSCs, 
and this was believed to contribute to reduced HSC function. Since Hoxa9, a critical 
target of MLL1 in both leukemia and normal hematopoiesis, only contributes modestly to 
HSC self-renewal, additional, unidentified genetic targets must be dysregulated in Mll1-
deficient HSCs to account for the profound functional defects [151].  These factors 
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remain to be elucidated. Furthermore, the role of additional TrG members in normal and 
malignant hematopoiesis has not been thoroughly evaluated. 
The TrG member ash1 was originally identified in Drosophila genetic screens 
seeking regulators of imaginal disc development [95]. It was later determined that ash1 
encodes a large protein containing a SET domain with putative histone methyltransferase 
activity [101]. Mammalian Ash1l encodes a similar SET domain-containing protein, and 
has been demonstrated to associate with actively transcribed gene loci, including at 
several Hox genes [130]. Recently, the Ash1l SET domain has been reported to have 
histone 3 lysine 36 dimethylase ability using in vitro biochemical assays, though the 
significance of this function in vivo has not been evaluated [133-135]. Interestingly, a 
recent report suggested that Ash1l functions in cultured hematopoietic cells and may 
cooperate with Mll1 to drive Hox gene expression [155]. Neither the function of Ash1l 
nor the idea of cooperativity with Mll1 has been evaluated rigorously with in vivo genetic 
models. 
In this report, we describe an essential role for the TrG member Ash1l in the 
maintenance of adult, but not fetal HSCs. Our data demonstrate that Ash1l is required for 
HSC self-renewal in the bone marrow and for the establishment of quiescence at the fetal 
to adult transition. Despite a 5-10-fold reduction in phenotypic BM HSCs and an inability 
to detect functional HSCs in transplantation assays, Ash1l-deficient mice do not progress 
to hematopoietic failure. This might be attributable to increased proliferation in 
progenitors downstream of HSCs that maintain hematopoiesis. Additionally, we 
demonstrate that Ash1l cooperates with Mll1 to maintain hematopoiesis at the level of 
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HSCs and progenitor cells. This report represents the first genetic demonstration of in 
vivo cooperativity between TrG members in mammals. 
RESULTS 
Ash1lGT/GT fetal HSCs develop and expand normally 
To examine the function of Ash1l in hematopoiesis, we utilized a gene trap 
insertion allele in which a potent splice acceptor cassette was placed in the first intron of 
the Ash1l locus (Figure 3.1A). This strategy resulted in a >90% reduction in full-length 
Ash1l transcripts in Lineage-Sca-1+cKit+ (LSK) hematopoietic progenitors both within 
fetal liver and bone marrow. E14.5 Ash1lGT/GT fetal livers had normal cellularity and 
mature myeloid, erythroid, and B lymphocyte population frequencies compared to wild-
type littermates (Figure 3.1B, C). To assess LT-HSC content, we utilized the SLAM 
(CD150+CD48-LSK) definition of LT-HSCs, as this strategy has been shown to robustly 
identify both fetal liver and adult bone marrow LT-HSCs [156, 157]. Phenotypic Ash1l-
deficient LT-HSCs were present at a normal frequency in the fetal liver (Figure 3.1D). 
This demonstrated that Ash1lGT/GT fetal LT-HSCs developed and expanded normally, and 
that they were capable of supporting hematopoiesis. 
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Figure 3.1. E14.5 Ash1lGT/GT fetal LT-HSCs expand normally and support hematopoiesis. (A) The 
Ash1lGT allele was generated by the insertion of a strong splice-acceptor gene trap cassette into the first 
intron of Ash1l. Homozygosity for this allele resulted in a >90% reduction in wild-type transcripts in fetal 
and adult LSK progenitors as indicated by qRT-PCR analysis with exon 1-2 spanning primers; (B) E14.5 
fetal liver cellularity is comparable between WT (+) and Ash1lGT/GT (GT) fetuses (N≥4 mice/genotype from 
2 independent experiments; mean +/- SEM); (C) Flow cytometric determination of myeloid (CD11b+Gr1+), 
erythroid (Ter119+), and B lymphocyte (CD19+B220+) frequencies in + and GT E14.5 livers showing no 
differences (N≥4 mice/genotype from 2 independent experiments; mean+/- SEM); (D) Flow cytometric 
analysis of E14.5 fetal livers showing normal frequencies of CD150+CD48–Lineage–Sca-1+cKit+ (SLAM) 
LT-HSCs in + and GT mice (data are representative of ≥ 4 mice/genotype; mean +/- SEM). Representative 
flow cytometry plots are shown. Numbers indicate the percentage of cells in each gate. 
Ash1lGT/GT LT-HSCs are profoundly depleted in the young adult bone marrow 
6-12 week old Ash1lGT/GT mice had normal bone marrow cellularity and normal 
frequencies of myeloid, erythroid, and B lymphocyte populations in the bone marrow 
(Figure 3.2A, C). Despite seemingly normal hematopoietic output, flow cytometric 
analysis revealed a 5-10-fold reduction in SLAM LT-HSCs compared to wild-type mice 
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(Figure 3.2D). To rule out that an altered surface phenotype was the cause for this 
reduction we demonstrated a similar 5-10-fold reduction in LT-HSCs using the 
alternative CD34-Flt3- definition (Figure 3.2E) [158]. This depletion did not impact 
myeloid progenitor output in CFU-GM assays, suggesting preserved myeloid progenitor 
function (Figure 3.2B). Surprisingly, despite the profound reduction in phenotypic LT-
HSCs, Ash1lGT/GT mice did not progress to bone marrow failure by 6 months of age and 
did not display further reductions in LT-HSC frequency (Figure 3.2F, G). These data 
indicated that Ash1lGT/GT LT-HSCs developed normally in fetuses, but became depleted in 
the young adult bone marrow. Despite this depletion, bone marrow output was preserved 
for at least 6 months without phenotypic worsening. 
 
 
 
 
 
 
 
 
	   41	  
	  
Figure 3.2. Ash1lGT/GT LT-HSCs are profoundly depleted in the BM by 6-12 weeks. (A) Young adult 
(6-12 week) BM cellularity is preserved between + and GT mice (N≥6 mice/genotype from at least 2 
independent experiments; means +/- SEM); (B) GT BM has normal ability to form myeloid colonies in 
CFU-GM assays (mean of technical triplicates representative of 2 independent experiments); (C) Flow 
cytometric determination of myeloid (CD11b+Gr1+), erythroid (Ter119+), and B lymphocyte (CD19+B220+) 
frequencies in + and GT young adult BM showing no differences (N≥2 mice/genotype; means +/- SEM); 
(D) Flow cytometric analysis of young adult mice (6-12 wk) showing GT mice had a >5 fold reduction in 
SLAM LT-HSCs (data are representative of ≥ 6 mice / genotype; means are shown +/- SEM); (E) Flow 
cytometric analysis demonstrating reduced LT-HSCs (CD34–FLT3–LSK), but not ST-HSCs (CD34+FLT3–
LSK) or MPPs (CD34+FLT3+LSK) in young adult + or GT mice (N≥4 mice/genotype from 2 independent 
experiments; means +/- SEM); (F) Analysis of mice aged at least 24 weeks demonstrates preserved bone 
marrow cellularity (N=6 mice/genotype from 3 independent experiments; means +/- SEM); (G) Flow 
cytometric analysis reveals a >5 fold reduction in 24 week old GT CD150+CD48–LSK LT-HSCs, as was 
true in young adult mice (N=6 mice/genotype from 3 independent experiments; means +/- SEM). 
Representative flow cytometry plots are shown. Numbers indicate the percentage of cells in each gate. 
*p<0.05, ***p<0.001. 
Neither fetal nor adult Ash1lGT/GT LT-HSCs are capable of sustaining long-term 
hematopoietic reconstitution 
Since Ash1lGT/GT mice were able to survive for at least 6 months with very few 
phenotypic HSCs, it was possible that a phenotypically abnormal but functional HSC 
compartment existed in the Ash1lGT/GT bone marrow. To test HSC function independent 
of phenotypic characteristics, we used whole fetal liver or bone marrow in competitive 
transplantation assays (Figure 3.3A). We chose the fetal liver as our initial source of LT-
HSCs since Ash1lGT/GT fetal livers did not have reduced phenotypic LT-HSCs. We found 
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that despite normal phenotypic LT-HSCs, Ash1lGT/GT fetal livers were incapable of 
sustaining myeloid, T cell, or B cell reconstitution in the peripheral blood (Figure 3.3B). 
Since a tri-lineage defect is suggestive of underlying LT-HSC dysfunction, we examined 
LT-HSC engraftment after 25 weeks. This revealed the absence of Ash1lGT/GT LT-HSCs 
in the bone marrow of transplant recipients, demonstrating that fetal Ash1lGT/GT LT-HSCs 
were already dysfunctional and incapable of supporting durable bone marrow 
hematopoiesis (Figure 3.3C) 
To determine if the young adult Ash1lGT/GT BM contained a phenotypically 
abnormal LT-HSC compartment capable of long-term reconstitution, we transplanted 
donor mice with Ash1lGT/GT or Ash1l+/+ BM mixed with an equal amount of competitor 
BM. We found that as was true with Ash1lGT/GT fetal liver LT-HSCs, Ash1lGT/GT BM LT-
HSCs did not support long-term tri-lineage output or durable LT-HSC BM engraftment 
(Figure 3.3D, E). Since there are examples of LT-HSCs performing poorly in 
competitive BM transplants but stably engrafting the BM in the absence of competition, 
we examined Ash1lGT/GT LT-HSC function in the absence of competition (Figure 3.3F) 
[48]. We found that 70% of Ash1lGT/GT BM recipients died within 10-150 days after 
transplantation, consistent with transient radioprotection but LT-HSC dysfunction 
(Figure 3.3G). Analysis of the surviving Ash1lGT/GT BM recipients revealed that these 
mice survived with host (CD45.1+) reconstitution and not Ash1lGT/GT LT-HSC 
engraftment (Figure 3.3H). Together, these data demonstrated that Ash1lGT/GT fetal liver 
and BM LT-HSCs were devoid of functional HSCs capable of stably engrafting the BM 
and sustaining long-term hematopoiesis.     
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Figure 3.3. Neither Ash1lGT/GT fetal liver nor young adult BM has a functional LT-HSC compartment 
in transplantation assays. (A) Experimental strategy: either Ash1l+/+or Ash1lGT/GT B6-CD45.2 bone 
marrow was mixed with WT B6-CD45.1 competitor bone marrow (1:1 ratio; 2.5X105 for fetal liver or 
5X105 of each for BM) and injected into lethally irradiated (9Gy) WT B6-CD45.1 recipient mice; (B) Flow 
cytometric analysis of the peripheral blood 4-25 weeks after fetal liver transplantation demonstrates a 
profound reduction of the Ash1lGT/GT bone marrow contribution to myeloid (CD11b+Gr1+), B cell 
(CD19+B220+), and T cell (CD3+) reconstitution (data are representative of ≥ 3mice/genotype); (C) 
Analysis of CD45.2/CD45.1 chimerism in the CD150+CD48–LSK LT-HSC compartment 25 weeks after 
transplantation demonstrates an absence of Ash1lGT/GT LT-HSCs (data are representative of ≥ 
3mice/genotype); (D) Flow cytometric analysis of peripheral blood 2-16 weeks after 6 wk-old BM 
transplantation shows a profound reduction of the Ash1lGT/GT BM contribution to myeloid (CD11b+Gr1+), B 
cell (CD19+B220+), and T cell (CD3+) reconstitution (data are representative of ≥ 4 mice/genotype); (E) 
Analysis of CD45.2/CD45.1 chimerism in the CD150+CD48–LSK LT-HSC compartment 16 weeks after 
transplantation demonstrates an absence of Ash1lGT/GT LT-HSCs (data are representative of ≥ 4 
mice/genotype); (F) Experimental Strategy: either Ash1l+/+or Ash1lGT/GT B6-CD45.2 bone marrow cells (106 
cells of each) were injected into lethally irradiated (9Gy) WT B6-CD45.1 recipient mice. (G) Mice were 
monitored for survival for the indicated period of time; (H) Flow cytometric analysis of surviving mice 
showing that Ash1lGT/GT recipients had only CD45.1 (Host)-derived LSK progenitors, while Ash1l+/+ 
recipients were reconstituted with CD45.2 (Donor) progenitors (data representative of at least 3 
mice/genotype). Representative plots are shown. Numbers indicate the percentage of cells in each gate. 
***p<0.001. 
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AshlGT/GT HSCs home to the bone marrow but do not properly establish or maintain a 
quiescent HSC pool  
Both bone marrow transplantation and the establishment of a BM HSC pool 
require homing of HSCs to the BM niche: transplantation requires that HSCs home from 
the site of injection to the bone marrow, while physiologic homing requires that HSCs 
migrate from the fetal liver to the bone marrow. Since Ash1lGT/GT mice lacked a stable 
HSC pool in both experimental models, it was possible that Ash1lGT/GT HSCs exhibited 
homing defects. To test this possibility, we analyzed the BM LT-HSC compartment in 
P10 mice by flow cytometry. These experiments revealed that Ash1lGT/GT neonatal mice 
had comparable frequencies of LT-HSCs in their BM, inconsistent with a homing defect 
(Figure 3.4A). We further found that normal Ash1lGT/GT LT-HSC frequency was 
preserved for at least 3 weeks after birth (data not shown). 
Assessment of neonatal BM LT-HSCs demonstrated that Ash1lGT/GT LT-HSCs 
had increased expression of cell surface CD34 as compared to wild-type mice (Figure 
3.4B). CD34 expression has been reported to mark fetal, but not adult mouse LT-HSCs 
[159, 160]. In addition, CD34 expression is upregulated on the surface of HSCs that are 
actively engaged in cell cycle activity [30, 159]. To test if Ash1lGT/GT BM LT-HSCs 
maintained a fetal-like transcription program, we crossed our mice with Sox17-GFP 
reporter mice [26]. Sox17 is a master regulator of the fetal HSC program and is expressed 
only in fetal HSCs and not in adult BM HSCs. We found that Ash1lGT/GT LT-HSCs 
properly expressed Sox17-GFP in the fetal liver and appropriately extinguished Sox17-
GFP by 2 weeks after birth (Figure 3.4C). Thus, Ash1l deficiency did not result in the 
maintenance of a fetal-like LT-HSC state.  
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To test if Ash1lGT/GT HSCs had an abnormal cell cycle status, we used both BrdU 
and Ki67-based staining strategies. P19 Ash1lGT/GT LT-HSCs showed a trend for 
increased BrdU incorporation suggesting aberrant cell cycle entry (Figure 3.4D). Ki67 
staining revealed that Ash1lGT/GT HSCs had a significantly reduced G0 fraction, increased 
entry into G1, and a trend for more HSCs in the later S-G2-M phases of the cell cycle 
(Figure 3.4E). Since HSCs exit the cell cycle in the BM between P14 and P21, this 
suggested that Ash1l-deficient HSCs failed to establish a normal quiescent stem cell pool 
[29]. 
Recent work has demonstrated that HSC BM quiescence is dependent on the 
expression of p27(Cdkn1b) and p57(Cdkn1c) [35, 36]. Gene expression analysis in LSK 
progenitors showed that P10 Ash1lGT/GT hematopoietic progenitors had markedly reduced 
expression of these two critical regulators of quiescence, though expression of 
p21(Cdkn1a), a CIP/KIP family member not implicated in the establishment of normal 
HSC quiescence, was not altered (Figure 3.4F). Collectively, these data suggested that 
Ash1lGT/GT HSCs failed to establish normal quiescence in the BM due to reduced p27 and 
p57 expression. 
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Figure 3.4. Ash1lGT/GT LT-HSCs home to the bone marrow but fail to establish quiescence. (A) Flow 
cytometric analysis of P10 BM demonstrated comparable frequencies of SLAM LT-HSCs between 
Ash1lGT/GT  and Ash1l+/+ littermates (data are representative of ≥ 9 mice / genotype; means +/- SEM); (B) 
P10 GT SLAM LT -HSCs had increased cell surface CD34 expression (data are representative of 4 
mice/genotype; means +/- SEM); (C) Flow cytometric analysis of Sox17-GFP expression in E15.5 fetal 
liver and P14 BM SLAM LT-HSCs shows that Sox17-GFP is present in fetal liver LT-HSCs and is 
appropriately extinguished in the P14 BM (N≥3 mice/genotype from 4 independent experiments; data 
points represent individual mice with bar at mean); (D) Representative flow cytometry plots showing P19 
Ash1lGT/GT SLAM LT-HSCs had increased cell cycle entry as indicated by increased BrdU incorporation 
(data are representative of ≥ 4 mice / genotype; means are shown + SEM); (E) Representative flow 
cytometry plots showing P19 Ash1lGT/GT SLAM LT-HSCs had a reduced G0 (quiescent fraction) and 
increased distribution into G1 and S-G2-M phases by Ki67 (data are representative of 5 mice/genotype; 
means are shown +/- SEM); (F) Reduced p27 and p57 gene expression in P10 Ash1lGT/GT LSK progenitors 
by qRT-PCR (3 individual sorted samples +/- SEM per genotype; expression relative to Hprt1). 
Representative plots are shown. Numbers indicate the percentage of cells in each gate. *p<0.05, **p<0.01, 
***p<0.001. 
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AshlGT/GT LT-HSCs and progenitors maintain increased cell cycle activity  
The cell cycle analyses described above provide a snapshot of cell cycle activity 
in LT-HSCs, but cannot provide detailed insight into cell cycle status over time. Since 
LT-HSCs were described as a slow-cycling cell population compared to differentiated 
cells in long-term pulse-chase experiments, detailed analysis of cell cycle history can 
identify putative HSCs with the least cell cycle entry [161]. To examine whether 
Ash1lGT/GT BM harbored cells with such very slow-cycling behavior, we bred Ash1lGT/GT 
mice to mice in which an H2B-GFP transgenic allele was inducible by tetracycline 
through the M2rtTa tetracycline activator [161]. This strategy allowed us to perform 
pulse-chase experiments and examine the long-term cell cycle activity of hematopoietic 
stem and progenitor cells (Figure 3.5A). We found that Ash1lGT/GT LT-HSCs had 
increased cell cycle activity sustained throughout the 6 week chase period as indicated by 
enhanced GFP dilution (Figure 3.5B). This increased cell cycle activity may reflect 
efforts of the few remaining phenotypic LT-HSCs to maintain hematopoietic 
homeostasis.  Interestingly, the Ash1lGT/GT LSK compartment as a whole had an even 
more robust increase in cell cycle activity than the LT-HSC compartment (Figure 3.5B). 
This suggested that increased proliferation in progenitors downstream of LT-HSCs might 
be the source of sustained hematopoietic output despite reduced LT-HSCs in Ash1lGT/GT 
mice. This finding could underlie the long-term survival and maintained hematopoietic 
output in Ash1lGT/GT mice. 
To further assess Ash1lGT/GT LT-HSC cell cycle activity, we challenged Ash1lGT/GT 
and control mice with the antimetabolite 5-fluorouracil (5-FU) (Figure 3.5C). 5-FU 
treatment is toxic to actively dividing cells, but spares quiescent cells including LT-
HSCs. Following a single dose of 5-FU, LT-HSCs robustly enter the cell cycle and 
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proliferate to restore hematopoietic homeostasis [31]. We found that a single treatment 
with 5-FU resulted in a nearly 2 log reduction in Ash1lGT/GT LT-HSCs compared to 
controls, thus amplifying the baseline LT-HSC reduction by 10-20-fold (Figure 3.5D). 
This further demonstrated that Ash1lGT/GT BM lacks a quiescent stem cell pool, and that 
remaining LT-HSCs were persistently engaged in cell cycle activity.  
 
	  
Figure 3.5. Ash1lGT/GT LT-HSCs and LSK progenitors sustain increased cell cycle activity. (A) 
Experimental strategy: Ash1l+/+or GT/GT with M2rtTA and H2B-GFP were maintained on doxycycline 
drinking water for 6 weeks to label hematopoietic cells with GFP. GFP dilution was monitored by flow 
cytometry after a 6 week chase period; (B) Flow cytometric analysis after the 6 week chase showing 
significantly increased GFP dilution in Ash1lGT/GT SLAM LT-HSCs and LSK progenitors compared to 
controls, demonstrating increased cell cycle activity (data are representative of ≥ 6 mice/genotype; means 
are shown +/- SEM); (C) Experimental Strategy: mice of indicated genotypes were injected with 150mg/kg 
5-fluorouracil (5-FU) and sacrificed 8 days later; (D) Flow cytometric analysis of SLAM LT-HSCs 
showing 2-log reduction in frequency and 2.5-log reduction in LT-HSC numbers in Ash1lGT/GT as compared 
to control mice after 5-FU exposure (N≥4 mice/genotype; graphs show means +/- SEM). Representative 
plots are shown. Numbers indicate the percentage of cells in each gate. *p<0.05, **p<0.01, ***p<0.001. 
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The Ash1lGT/GT niche supports donor LT-HSC engraftment in the absence of 
conditioning 
Few reports describe HSC genetic defects that permit donor HSC engraftment in 
the absence of conditioning [61, 162]. We reasoned that since Ash1lGT/GT BM had 
profoundly reduced LT-HSCs, and remaining phenotypic LT-HSCs were non-functional 
in transplantation assays, there might be available BM niche space and/or defective HSCs 
that could be out-competed by wild-type donor BM. Either scenario could permit 
engraftment of donor BM without conditioning. To examine this possibility, we 
transplanted wild-type (CD45.2+) or Ash1lGT/GT (CD45.2+) mice with wild-type 
(CD45.1+) bone marrow (Figure 3.6A). We found that in 4/5 Ash1lGT/GT recipients, stable 
tri-lineage hematopoietic output from donor BM could be detected in the peripheral blood 
for at least 12 weeks (Figure 3.6B). We further determined that this output resulted from 
wild-type LT-HSCs stably engrafting the Ash1lGT/GT BM (Figure 3.6C). As expected, 
minimal to no donor engraftment was detected in wild-type recipients. These data further 
support a model in which Ash1l is cell-autonomously required for the maintenance of LT-
HSCs in the BM niche. The combination of vacant niches and profound LT-HSC 
dysfunction in Ash1lGT/GT BM was suitable for engraftment by donor cells without any 
conditioning. Importantly, these data demonstrated that the Ash1lGT/GT niche was not 
itself defective, as it was able to support stable engraftment by wild-type donor LT-
HSCs.  
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Figure 3.6. Ash1l deficiency allows LT-HSC engraftment in the absence of conditioning. (A) 
Experimental strategy: Ash1lGT/GT or +/+  (CD45.2+) mice were transplanted with 2 doses of 2 X 107 BM 
(CD45.1+) separated by 1 week without irradiation; (B) Flow cytometric analysis of peripheral blood of 
transplant recipients demonstrates significant output from donor BM in myeloid (CD11b+Gr1+), B cell 
(CD19+B220+), and T cell (CD3+) lineages in 4/5 Ash1lGT/GT recipients, but in 0/6 WT recipients. 
Reconstitution was sustained for at least 12 weeks (data are representative of ≥ 5 mice/genotype); (C) Flow 
cytometric analysis of LT-HSC compartment demonstrates stable donor (CD45.1+) LT-HSC engraftment in 
4/5 Ash1lGT/GT recipients, but in 0/6 WT recipients. Representative plots are shown. Numbers indicate the 
percentage of cells in each gate. *p<0.05. 
Ash1l cooperates with Mll1 to maintain hematopoiesis 
Studies in Drosophila revealed that members of the TrG can functionally 
cooperate with one another to maintain homeobox gene expression [97]. This 
phenomenon has not been assessed in mammals in vivo. We reasoned that if mammalian 
TrG members cooperated with one another, they might share a subset of target genes and 
functional effects. Mll1, the mammalian homolog of Drosophila trithorax, was shown to 
	   51	  
regulate a number of Homeobox genes including Meis1, Hoxa9, and Hoxa10, all of which 
are known to be essential for HSC self-renewal. We found that P10 Ash1lGT/GT LSK 
progenitors had reduced expression of Hoxa5, Hoxa9, Hoxa10, and Meis1, with Hoxa9 
and Meis1 being the most profoundly affected (Figure 3.6). Importantly, Mll1 levels 
were not changed in these progenitors, demonstrating that effects of Ash1l deficiency on 
Hox gene expression were not secondary to reduced Mll1 levels. This suggested that 
Ash1l and Mll1 shared a subset of genetic targets known to be essential for LT-HSC 
function, and thus that they may cooperatively function to maintain hematopoietic 
homeostasis. 
 
	  
Figure 3.7. Ash1lGT/GT neonatal LSKs have reduced Hox gene expression independent of Mll1. 
Reduced Hox gene expression in P10 Ash1lGT/GT LSK progenitors by qRT-PCR (3 individual sorted samples 
+/- SEM per genotype; expressed relative to Hprt1). *p<0.05, **p<0.01. 
To examine if Ash1l and Mll1 cooperate to maintain hematopoietic homeostasis, 
we intercrossed Mll1fl/fl Mx1-cre+mice with Ash1lGT [68]. This system allowed us to 
delete Mll1 via poly(I:C) injection (Figure 3.8A). Using this model, we found that 
combined deficiency for Mll1 and Ash1lGT/GT resulted in an acute reduction in bone 
marrow cellularity, suggesting that these mice developed bone marrow failure (Figure 
3.8B). To determine if loss of hematopoietic progenitor cells underlied bone marrow 
failure, we analyzed the LT-HSC and downstream progenitor compartments by flow 
cytometry. Flow cytometric analysis of LT-HSCs and hematopoietic progenitors 
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demonstrated that Ash1lGT/GTMll1fl/flMx1-cre+ mice had profound reductions in LT-HSCs 
and LSK progenitors (Figure 3.8C, D, E). In addition, Ash1lGT/+Mll1fl/+Mx1-cre+ mice 
had fewer LT-HSCs than Ash1lGT/+ or Mll1fl/+Mx1-cre+mice, suggesting that LT-HSCs 
had a unique sensitivity to the observed functional interaction between Mll1 and Ash1l. 
Flow cytometric analyses further revealed that CD34-SLAM LT-HSCs, one of the most 
quiescent HSC subsets that can be identified with surface markers, were profoundly 
reduced in Ash1lGT/GTMll1fl/flMx1-cre+mice as well as in Ash1lGT/+Mll1fl/+Mx1-cre+ mice 
(Figure 3.8F). This suggested that Ash1l and Mll1 cooperate to maintain quiescent 
HSCs. Together, these findings identified cooperativity between Mll1 and Ash1l in 
maintaining hematopoietic stem and progenitor cells. This is the first in vivo 
demonstration of a functional interaction between TrG members in mammals. 
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Figure 3.8. Combined Ash1l and Mll1 deficiency results in acute LT-HSC and LSK depletion. (A) 
Experimental strategy: mice of indicated genotypes were injected 5X with 20ug of poly(I:C); (B) Reduced 
bone marrow cellularity in Ash1lGT/GTMll1fl/flMx1-cre+mice (data are representative of ≥ 2 mice/genotype; 
mean +/- SEM); (C) Flow cytometric analysis showing severe reductions in CD34- SLAM LT-HSCs, 
SLAM LT-HSCs, and LSK progenitors in Ash1lGT/GTMll1fl/flMx1-cre+mice and reduced CD34- SLAM LT-
HSC frequency Ash1lGT/+Mll1fl/+Mx1-cre+mice; (D, E) LT-HSC and LSK absolute cell numbers reflecting 
profound defect in Ash1lGT/GTMll1fl/flMx1-cre+mice and reduced LT-HSC numbers in Ash1lGT/+Mll1fl/+Mx1-
cre+mice (data are representative of ≥ 2 mice/genotype; mean +/- SEM); (F) Frequencies of CD34- SLAM 
LT-HSCs emphasizing reduction in Ash1lGT/+Mll1fl/+Mx1-cre+ BM. Representative plots are shown. 
Numbers indicate the percentage of cells in each gate.  
Previous studies indicated that the cofactor menin is required for Mll1 targeting to 
at least a subset of gene loci [117, 118, 147, 148]. Combining the Ash1lGT allele with 
Men1fl/fl Mx1-cre+ mice thus provided a means to independently verify the described 
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functional interaction between Ash1l and Mll1 in hematopoiesis [163]. Men1 excision 
was achieved by poly(I:C) injection, and this allowed us to ablate menin-dependent Mll1 
function in the hematopoietic system (Figure 3.9A). Analysis of the bone marrow 
compartment 3 weeks after the initiation of poly(I:C) revealed a significant reduction in 
BM cellularity in Ash1lGT/GTMen1fl/flMx1-cre+mice (Figure 3.9B). This suggested that 
mice progressed to bone marrow failure in the absence of Ash1l and menin/Mll1, 
consistent with the development of profound neutropenia and thrombocytopenia (Figure 
3.9C, D). Additionally, the combination of a single Ash1lGT allele with Men1 inactivation 
(Ash1lGT/+Men1fl/flMx1-cre+) resulted in reduced platelets as compared to either Ash1lGT/+ 
or Men1fl/flMx1-cre+ peripheral blood. This suggested that Men1 loss sensitized the bone 
marrow to Ash1l haploinsufficiency, further indicating cooperativity between menin/Mll1 
and Ash1l. 	  
 
Figure 3.9. Combined deficiency of Ash1l and Men1 results in rapid progression to frank 
hematopoietic failure. (A) Experimental strategy: mice of indicated genotypes were injected 5 X with 
20ug of poly(I:C); (B) Reduced bone marrow cellularity in Ash1lGT/GTMen1fl/flMx1-cre+mice compared to 
wild-type (data are representative of ≥ 5 mice/genotype; mean +/- SEM); (C) Complete blood count 
analysis of peripheral blood platelets showing thrombocytopenia in AshlGT/GTMen1fl/flMx1-cre+ mice within 
3 weeks of poly(I:C) injection (N≥3 mice/genotype from 3 independent experiments; means +/- SEM); (D) 
Complete blood count analysis of peripheral blood neutrophils demonstrating profound neutropenia in 
	   55	  
AshlGT/GTMen1fl/flMx-1-cre+ mice within 3 weeks of poly(I:C) injection (N≥3 mice/genotype from 3 
independent experiments; mean +/- SEM). *p<0.05, ***p<0.001 compared to wild-type. For comparisons 
between AshlGT/+Men1fl/flMx-1-cre+and AshlGT/+ or Men1fl/flMx1-cre+: ## p<0.01 compared to Ash1lGT/+; + 
p<0.05 compared to Men1fl/flMx1-Cre+. 
To determine if bone marrow failure occurred concurrently with hematopoietic 
stem and progenitor cell depletion, as observed above, we analyzed these populations by 
flow cytometry following Men1 excision. We found that Ash1lGT/GTMen1fl/flMx1-cre+ LT-
HSCs were severely decreased, and that this occurred concurrently with a profoundly 
depleted LSK progenitor compartment (Figure 3.10A, B). Ash1lGT/+Men1fl/flMx1-cre+ 
resulted in reduced LT-HSCs compared to either Ash1lGT/+ or Men1fl/flMx1-cre+ LT-HSC 
compartments, demonstrating that menin/Mll1 loss sensitized LT-HSCs to reduced Ash1l 
levels. Despite the LT-HSC depletion, however, the pool of downstream progenitors was 
not profoundly depleted unless both alleles of Men1 and Ash1l were mutated. Together, 
these findings demonstrated that combined Men1 and Ash1l deficiency reproduced the 
bone marrow failure phenotype observed in the setting of combined Mll1 and Ash1l 
deficiency. These findings further indicated a robust functional cooperativity between 
menin/Mll1 and Ash1l in hematopoietic stem and progenitors, and thus a critical role in 
maintaining hematopoietic homeostasis.  
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Figure 3.10. Profound LT-HSC and LSK progenitor depletion underlies hematopoietic failure in 
mice with combined Ash1l and Men1 deficiency. (A) Flow cytometric analysis showing severely reduced 
LT-HSC and LSK progenitor compartments in Ash1lGT/GTMen1fl/flMx1-cre+mice and reduced LT-HSC 
frequency Ash1lGT/+Men1fl/flMx1-cre+mice; (B) LT-HSC and LSK frequencies and absolute cell numbers 
reflecting profound defect in Ash1lGT/GTMen1fl/flMx1-cre+mice and reduced LT-HSC frequency and absolute 
numbers in Ash1lGT/+Men1fl/flMx1-cre+mice (data are representative of ≥ 5 mice/genotype; mean +/- SEM). 
Representative plots are shown. Numbers indicate the percentage of cells in each gate. *p<0.05, **p<0.01, 
***p<0.001 compared to wild-type. For comparisons between AshlGT/+Men1fl/flMx-1-cre+and AshlGT/+ or 
Men1fl/flMx1-cre+: ## p<0.01 compared to Ash1lGT/+; ++ p<0.01 compared to Men1fl/flMx1-Cre+. 
DISCUSSION 
Our findings identify that LT-HSC self-renewal is dependent on Ash1l. When 
Ash1l levels were profoundly reduced due to homozygosity for our gene trap allele, LT-
HSCs had an impaired ability to establish and maintain quiescence. Ash1l-deficient HSCs 
developed and expanded normally in the fetal liver and initially seeded the bone marrow. 
Once in the bone marrow, these LT-HSCs failed to upregulate the CDKIs p27 and p57, 
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leading to markedly reduced numbers of quiescent adult HSCs. Since fetal HSCs are 
known to actively transit through the cell cycle, it was tempting to speculate that these 
findings were the result of an inability of HSCs to extinguish the fetal program upon 
reaching the bone marrow [29, 164]. However, expression of Sox17, the master regulator 
of the fetal HSC transcriptional program, was properly repressed in the bone marrow. 
This finding indicated that the reduced ability for Ash1lGT/GT LT-HSCs to establish 
quiescence was independent of the transcriptional transition from the fetal state to the 
adult state. This suggests that Ash1l may be a novel key regulator of the cell cycle 
changes associated with the fetal to adult HSC transition. 
Ash1lGT/GT bone marrow had profoundly reduced LT-HSC numbers, but 
maintained normal mature hematopoietic cell output. This paradox could have been 
explained by phenotypically abnormal, but functional HSCs residing in the Ash1lGT/GT 
bone marrow. However, this was disproven as young adult Ash1lGT/GT bone marrow could 
engraft lethally irradiated recipients in neither competitive nor non-competitive 
transplantation assays. Based on this gold standard approach, we could not detect LT-
HSC function in the Ash1lGT/GT bone marrow. We thought that this inability to detect LT-
HSC function could have been because of the rarity of Ash1lGT/GT LT-HSCs; perhaps we 
transplanted too few bone marrow cells to include adequate LT-HSC numbers. To rule 
out this hypothesis, we transplanted Ash1lGT/GT fetal liver cells. This allowed us to 
normalize LT-HSC frequency, as both Ash1lGT/GT and Ash1l+/+ had comparable LT-HSC 
compartments. Strikingly, we could not detect functional LT-HSCs in this transplantation 
setting either. This demonstrated that Ash1lGT/GT LT-HSCs could not stably engraft the 
bone marrow niche. This could be because Ash1lGT/GT LT-HSCs cannot respond to niche 
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factors required for stable engraftment and quiescence. Among these, thrombopoietin and 
TGF-β have been linked to promoting quiescence through CDKI regulation, and 
thrombopoietin has additionally been linked to promoting Hox gene expression [32, 33, 
38]. It is thus possible that Ash1l may be necessary for signaling downstream of essential 
niche factors required for bone marrow HSC quiescence and long-term function. 
Interestingly, Ash1l-deficient mice did not progress to frank hematopoietic failure 
despite a severely depleted phenotypic LT-HSC compartment and a lack of detectable 
HSC function in transplantation assays. Increased H2B-GFP dilution exhibited by 
Ash1lGT/GT LT-HSCs may suggest that this severely reduced LT-HSC compartment 
elevated its proliferative output to maintain hematopoietic homeostasis. Indeed, actively 
proliferating HSCs have reduced engraftment potential in transplantation assays, and this 
could explain the observed difference between steady-state hematopoiesis and 
transplantation models in our system [29, 154]. Alternatively, the lack of detectable HSC 
function in transplantation assays could suggest that Ash1lGT/GT LT-HSCs are in fact non-
functional and do not contribute to steady-state hematopoiesis. In this scenario, the robust 
dilution of H2B-GFP in LSK progenitors could indicate that progenitors downstream of 
LT-HSCs are responsible for maintained hematopoietic homeostasis. The fact that these 
progenitors actively proliferated but did not become depleted could suggest that they 
possess significant self-renewal activity. Such would be the case because if these cells 
strictly underwent differentiating divisions, they would be predicted to become depleted 
over time. This self-renewal activity would not be detectable in transplantation assays 
because quiescence is required for engraftment, as described above. This is an intriguing 
possibility in light of recent work in thymocytes indicating that in the absence of fresh 
	   59	  
progenitors seeding the thymus, downstream progenitors could self-renew to maintain T 
cell output [165, 166]. This was striking because thymic progenitors were not previously 
shown to have self-renewal potential, and this was only revealed in the absence of 
continuous progenitor input. Perhaps the absence of functional LT-HSCs in our model 
revealed intrinsic self-renewal potential in downstream progenitors, similar to what was 
observed in the thymus. 
Genetic models of HSC dysfunction that support non-ablative transplantation are 
rare findings in hematopoietic biology [61, 162]. In the Ash1lGT/GT system, successful 
engraftment in non-ablative transplantation experiments provided critical proof that the 
Ash1l-deficient BM niche was not grossly defective, as it could efficiently support the 
maintenance of wild-type LT-HSCs. Stable wild-type LT-HSC engraftment into the 
Ash1l-deficient niche suggests that niche spaces were available due to LT-HSC depletion 
and/or that remaining Ash1lGT/GT LT-HSCs were dysfunctional to an extent that they 
could be out-competed or displaced by wild-type LT-HSCs. Either scenario is consistent 
with extreme LT-HSC dysfunction when Ash1l levels are reduced.  
The functional interaction between Mll1 and Ash1l in LT-HSC and progenitor 
maintenance was a novel demonstration of the evolutionarily conserved cooperativity 
between members of the TrG. This notion has been explored in Drosophila, but had not 
been previously described in mammals. Perhaps the most striking demonstration of this 
was the finding that a single Ash1lGT allele amplified LT-HSC depletion in Men1-
deficient and Mll1 heterozygous mice. This dominant phenotypic enhancement is 
reminiscent of criteria used to initially identify TrG members in Drosophila [97].  Given 
that both Mll1 and Ash1l are required for Hox gene expression, it is possible that both 
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proteins act non-redundantly to promote transcription. Indeed, both Ash1lGT/GT and Men1-
deficient hematopoietic progenitors displayed a reduced, but not absent expression of 
Hoxa9, suggesting multifactorial regulation of this locus [150]. Additional studies 
assessing whether this cooperativity is due to SET domain catalysis or perhaps through 
promoting the formation of larger, transcription-promoting protein complexes are 
required. Such studies will provide insight into the complex regulation of hematopoietic 
development and HSC function.  
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CHAPTER 4.  SHELTERIN PROTEINS: FUNCTIONS IN 
TELOMERE PROTECTION AND HEMATOPOIESIS 
INTRODUCTION 
Telomere biology has historically been studied in the context of the end replication 
problem. This problem arises because the DNA replication machinery requires an initial 
RNA primer to provide a 3’ hydroxyl group to begin DNA strand synthesis. This primer 
is removed, and as a consequence, the 3’ end of the template strand is not efficiently 
replicated. Consequently, this process could result in the loss of essential genetic material 
if such material was encoded at the very 3’ end of chromosomes. Telomeres provide a 
molecular buffer to such erosion, and thus protect essential genetic material during 
replicative stress. In long-lived proliferative stem cell populations, the ribonucleoprotein 
telomerase maintains telomere length [55-57, 167-170]. In recent years, we have learned 
that telomeres alone are not sufficient to protect the chromosome ends, as exposed DNA 
of any form triggers recognition by DNA damage machinery (the “end protection 
problem”). Six proteins, known as the shelterin complex, bind telomeric ends and prevent 
this aberrant DNA damage recognition. These proteins, Trf1, Trf2, Rap1, Tin2, Pot1 and 
Tpp1, not only protect telomeres, but also recruit telomerase and regulate telomere length 
[171]. In this chapter, we review the functions of individual shelterin proteins and discuss 
our current understanding of how they contribute to hematopoietic homeostasis. 
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TELOMERES AND THE DDR 
Telomeres consist of a single-stranded, G-rich overhang preceded by a double-
stranded region. Shelterin proteins bind to both the double- and single-stranded 
components (Figure 4.1). Without shelterin binding and end protection, telomeres are 
recognized as chromosomal aberrations and detected by a robust DDR. Exposure of the 
single-stranded G overhang elicits a robust ataxia telangectasia and Rad3-related (ATR)-
mediated DDR [172, 173]. This is because, when uncovered, the single-stranded 
overhang is indistinguishable from single-stranded DNA that arises from replication fork 
stalling. Such single-stranded DNA is recognized and bound by replication protein A 
(RPA) [174]. RPA/ssDNA complexes are bound by ATR-interacting protein (ATRIP), 
which in turn recruits ATR.  Additionally, RPA/ssDNA is bound by the Rad9-Rad1-Hus1 
(9-1-1) complex through an interaction with Rad17 [175]. This complex recruits TopBP1, 
which activates ATR through a poorly defined mechanism [176-178]. Activated ATR 
phosphorylates Chk1 and can trigger cell cycle arrest through direct regulation of cyclin-
dependent kinases or p53 activation (reviewed in [179-181]). This arrest is believed to 
allow cells the opportunity to repair DNA aberrations. 
Exposure of the double-stranded portion of the telomere results in aberrant 
recognition of the telomere as a double-stranded break. Double-stranded breaks are 
sensed and bound by the Mre11-Rad50-Nbs1 (MRN complex) [182]. MRN recruitment 
triggers ataxia telangectasia mutated (ATM) kinase binding and enhances ATM 
interaction with Chk2 and p53 [182-184]. Activated Chk2 can then enforce cell cycle 
arrest both directly and through p53 activation (reviewed in [179]). A growing body of 
work additionally supports that ATM may activate ATR, suggesting that as the DDR 
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evolves in response to double-stranded breaks, both kinases may be activated to promote 
more robust cell cycle slowing and repair processes [185]. 
DDR activation at the telomere primarily proceeds to activation of non-
homologous end joining (NHEJ) and homologous recombination (HR), although complex 
genetic models indicate that additional repair pathways may be activated [186]. A 
growing body of literature, described in detail below, indicates that exposure of the 
double-stranded portion of the telomere activates NHEJ repair, while exposure of the 
single-stranded portion activates HR [172, 173, 187]. As NHEJ attempts to repair DNA 
damage through re-joining perceived DNA breaks, this results in the fusion of unrelated 
chromosomes in the context of telomere instability. Since telomeric HR attempts to repair 
lesions through the use of homologous sister chromatid templates, attempts at HR are 
reflected by the exchange of material between sister chromatids, or sister chromatid 
fusions. DNA abnormalities consistent with NHEJ and HR are identifiable in metaphase 
chromosome preparations depending on the model of telomere deprotection. 
THE FUNCTION OF INDIVIDUAL SHELTERIN PROTEINS IN TELOMERE PROTECTION 
DDR components, including ATR and ATM, are recruited to telomeres during 
cellular proliferation to promote efficient telomere replication [188]. These proteins are 
required to alleviate replication fork stalling triggered by the repetitive telomeric DNA 
sequence and to promote secondary structure formation required for telomere stability. 
Studies using murine embryonic fibroblasts (MEFs) showed that individual shelterin 
proteins have specific functions in suppression of the DNA damage response and 
telomere regulation (Figure 4.1). This complex has three general classes of proteins: 
those that bind the double-stranded portion of telomeric DNA, those that bind the single-
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stranded portion of telomeric DNA, and those that do not bind DNA but instead interact 
with other shelterin proteins.  
 
	  
Figure 4.1. The function of individual shelterin proteins in telomere protection. Pot1 (in mice Pot1a) 
prevents recognition of the single stranded telomeric overhang from an ATR-Chk1 mediated DDR. 
Recognition by this pathway results in attempts at DNA repair through homologous recombination (HR). 
Trf2 prevents recognition of the double-stranded portion of the telomere from an ATM-Chk2 mediated 
DDR. ATM activation results in attempts at telomere repair through nonhomologous end-joining (NHEJ). 
Pot1 is linked to the shelterin complex through a Tpp1/Tin2 tether. Rap1, a Trf2 interacting protein, plays a 
poorly defined role in preventing aberrant telomeric HR. 
Trf1 
Trf1 and Trf2 directly bind doubled-stranded telomeric DNA but play unique 
roles in telomere protection [189-192]. Over-expression of Trf1 in a human telomerase 
positive cell line resulted in telomere shortening, while a dominant negative Trf1 elicited 
a telomere lengthening phenotype [193]. These data suggest that Trf1 is a negative 
regulator of telomere length. Additional work led to the proposal that Trf1, along with 
Trf2, is not involved in the direct regulation of telomerase expression or activity, but 
rather is linked to the formation of higher ordered structures that prevent telomerase 
access to telomeres [194]. This telomerase inaccessible, or closed state, was predicted to 
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be dependent on the number of Trf1/2 proteins bound to the telomeric end. Thus, limiting 
Trf1/2 abundance or shortening the telomere to a point that restricted the number of 
bound Trf1/2 proteins should result in telomerase recognition and subsequent telomere 
lengthening.  
Studies in MEFs demonstrated that when Trf1 was conditionally inactivated, the 
DNA replication machinery stalled at the telomere, and abundant gaps, known as fragile 
sites, could be observed in metaphase chromosomes [195, 196]. Such chromosomal 
aberrations have been linked to chromosomal instability and cancer. This work suggested 
an interesting role in Trf1-mediate regulation of efficient telomere replication. Trf1-
deleted MEFs rapidly progressed to cellular senescence in a p53 and retinoblastoma-
dependent fashion [195, 196]. Conflicting data exist regarding the upstream components 
of DNA damage signaling following Trf1 deletion. One report documented the presence 
of chromosomal fusions and a robust DDR consisting of both ataxia telangectasia 
mutated (ATM) kinase and ataxia telangectasia and Rad3-related (ATR) kinase activation 
[196]. The second report did not document chromosomal fusions and demonstrated an S-
phase specific ATR response [195]. The nature of the discrepancy between these reports 
is unclear, though it may be attributable to different Cre-mediated Trf1 deletion strategies 
and slightly different experimental timelines. It is also possible that ATM/ATR activation 
was not directly due to Trf1 deletion, but was instead secondary to replication fork 
collapse and accumulating genetic lesions following Trf1 deletion.  
Mouse models of Trf1 loss have demonstrated critical roles for Trf1 in 
developmental and cancer biology. Constitutive deletion of Trf1 results in embryonic 
lethality before E6.5 [197]. This lethality did not appear to occur concurrently with 
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telomere instability, as fragile site formation or chromosomal fusions were not observed. 
Furthermore, p53 deletion, which rescued MEF phenotypes, only modestly extended 
embryo survival and did not rescue embryonic lethality. This suggested a critical role for 
Trf1 in early development. Deletion of Trf1 in the bone marrow resulted in a progression 
to bone marrow failure within 3 weeks (discussed in detail below) [59]. This failure was 
linked to p53/p21 activation, telomeric DDR activation, telomeric shortening, and 
eventual cellular senescence. The significance of p53 activation in these processes was 
not directly tested. Deletion of Trf1 in the skin resulted in severe epidermal 
developmental defects and mortality due to the loss of skin barrier function [196]. 
Interestingly, p53 deletion in the skin was sufficient to rescue developmental defects. 
However, this rescue strategy resulted in squamous cell carcinoma development, 
demonstrating that underlying genetic instability due to Trf1 loss was tumorigenic. These 
data are intriguing in that they suggest that different developmental processes or cell 
types may differentially activate DDR signaling in response to shelterin defects. 
Furthermore, they suggest that limiting the DDR through p53 ablation, though capable of 
rescuing some developmental processes, can result in sustained chromosomal instability 
sufficient to initiate tumorigenesis. 
Trf2 
Trf2 directly protects telomere from an ATM-dependent DDR [172, 173, 198, 
199]. Loss of Trf2 triggers telomeric fusions as a result of ATM-mediated activation of 
non-homologous end-joining (NHEJ) [187, 199, 200]. Interestingly, Trf2 loss was found 
to activate a DNA damage response in all phases of the cell cycle, though NHEJ activity 
was restricted to G1 [199, 201]. These data support the idea that Trf2 loss induces 
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telomeric DDR activation at all times, rather than eliciting a DNA damage response 
secondary to replication fork stalling during strand replication (unlike Trf1 loss).  
Trf2, like Trf1, also seems to play a role in telomere length homeostasis. 
Overexpression of Trf2 in telomerase positive human cells resulted in progressive 
telomere shortening, and telomere elongation was observed when Trf2 levels decreased 
[194]. This finding was not related to regulation of telomerase expression or activity, and 
may have been due to decreased telomerase access to telomeres in the presence of 
increased Trf2, as discussed above. 
As seen for Trf1, Trf2 knockouts are embryonic lethal, suggesting broad roles in 
early development [198]. Genetic p53 deficiency did not rescue this embryonic 
phenotype. Interestingly, overexpression of Trf2 in the skin resulted in hyperpigmentation 
and predisposed mice to squamous cell carcinomas [202]. Consistent with the previously 
described human cell line data, epithelial studies from mice with Trf2 overexpression 
revealed prominent telomere shortening. This shortening was not the result of telomerase 
dysfunction. If telomerase deficiency was coupled with Trf2 overexpression, 
tumorigenesis was significantly accelerated [203]. This occurred as the result of enhanced 
telomere dysfunction and fusion events in the setting of increased Trf2 and telomerase 
deficiency. These data suggest that while initial telomere shortening due to increased 
Trf2 is not due to telomerase dysfunction, the addition of telomerase dysfunction further 
destabilizes the genome to increase tumorigenesis. 
Rap1 
Rap1 does not bind telomeric DNA, but instead is localized to the telomere by an 
interaction with Trf2 [204, 205]. Rap1 was originally identified as suppressing NHEJ at 
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the telomere [206-208]. Subsequent work failed to identify a function for Rap1 in 
suppressing NHEJ or in preventing ATM activation [204, 209, 210]. Instead, Rap1-
deficient MEFs had increased telomeric homologous recombination (HR) events without 
evidence of DDR activation [209, 210]. These data indicated that Rap1 is not involved in 
the suppression of a telomeric DNA damage response, although it seems to be involved 
in regulation of HR at telomeres. 
Rap1 deficiency does not result in embryonic death in mice suggesting that 
vigorous DDR activation in embryonic development is the key determinant of the 
embryonic lethality observed in Trf1- and Trf2-deficient mice. [210]. Interestingly, 
despite seemingly normal development, Rap1 deletion in the skin results in 
hyperpigmentation, telomere shortening, and increased DDR activation in adulthood. 
Together, these findings suggest that Rap1 does indeed play an important role in 
physiological telomere homeostasis. Furthermore, studies with Rap1 demonstrate the 
need to consider the physiological function of individual shelterin components in a 
developmental context rather than solely in cell line-based studies. 
Pot1 
Pot1 is an evolutionarily conserved protein that directly binds to the single-
stranded G overhang of telomeres [211-213]. This binding is dependent on 
heterodimerization with Tpp1 (discussed below) [172, 214-217]. At telomeres, Pot1 plays 
two critical roles in homeostasis. The first is to suppress an ATR-mediated DNA damage 
response that would result in aberrant HR [218]. Work using chicken Pot1 demonstrated 
that ATR activation causes growth arrest as cells transition into the G2 phase of the cell 
cycle [219]. The second critical Pot1 function is the regulation of G strand overhang 
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length [218]. Following telomere replication, exonucleolytic processing of the 5’ C strand 
is required to generate the 3’ G strand overhang. Initial work suggested that Pot1 
regulates the extent of 5’ resection and that the absence of Pot1 results in excessive 5’ 
resection and extended 3’ overhangs. Subsequent studies in mice, discussed below, 
revealed a different mechanism by which Pot1 prevents this resection [220].  
In mice, the Pot1 gene has undergone a duplication event resulting in two Pot1 
genes: Pot1a and Pot1b [221]. This duplication established a separation of the two main 
POT1 functions between murine Pot1a and Pot1b. Biochemical analysis of the murine 
proteins demonstrated that the N-terminus of Pot1a is the critical element for ATR 
inhibition, while the C-terminus of Pot1b prevents excessive 5’ resection [221, 222]. 
Pot1b may play a minor role in end protection, as the combined loss of Pot1a and Pot1b 
elicits a more robust telomeric DDR than Pot1a loss alone [221]. Furthermore, only 
combined Pot1a/b loss resulted in a significant increase in telomeric instability and 
homologous recombination [218, 221]. Additionally, Pot1a/b loss caused increased 
endoreduplication (replication of DNA without cellular division) in MEFs [221]. As a 
result of this phenomenon, MEFs with >4N DNA content accumulate in culture. 
The DDR induced by Pot1a loss resulted in a p53-mediated induction of 
senescence [222]. This increased senescence was demonstrated in the context of growth 
slowing in Pot1a-/- MEF cultures and increased p21 and phospho-p53 levels. 
Furthermore, this senescence could be by p53 inactivation in Pot1a-/- MEFs. 
Though Pot1b loss did not initiate robust DDR activity, it did result in significant 
telomeric shortening after many cell culture passages [223, 224]. While Pot1b loss did 
not cause chromosomal instability alone, the combination of Pot1b loss with telomerase 
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deficiency resulted in extensive chromosomal fusions [223]. Furthermore, when Pot1b-/- 
MEFs lost a single copy of the gene encoding the telomerase RNA, rendering cells 
haploinsufficient for telomerase activity, telomere shortening was exacerbated [223, 224]. 
These MEFs also had a significant increase in chromosomal fusions [223, 224]. Pot1 loss 
combined with telomerase haploinsufficiency induced ATR activation, though it is not 
clear if this was due to acute deprotection or resulted from increased genomic instability 
due to excessive telomere shortening [224]. 
Elegant studies recently revealed the mechanism by which Pot1b prevents 
excessive 5’ C-strand resection [220]. Two nucleases, Apollo and Exo1, act to modify 
telomere length following telomere elongation. Apollo initiates resection, while Exo1 
extends 5’ resection. Pot1b limits Apollo-mediated resection. Furthermore, Pot1b is 
involved in the recruitment of the CST complex to the telomeric end. This complex is a 
DNA polymerase α cofactor that facilitates strand fill-in of the 5’ C strand. Briefly, the 
CST complex aids in the initiation of lagging strand synthesis at the 5’ telomeric end 
after resection (reviewed in [225]). This fill-in thus limits the relative length of the 3’ 
overhang. Pot1b therefore plays two roles in regulating 3’ overhang length by limiting 5’ 
resection and facilitating 5’ strand fill-in. It remains to be determined if this mechanism is 
conserved in humans. 
In mice, Pot1a deletion results in early embryonic lethality, while Pot1b-deficient 
mice are born in mendelian ratios with normal fertility [221, 222, 224]. This suggested a 
critical role for Pot1a but not Pot1b in early development. Despite initial fertility, Pot1b-
deficient male mice eventually become infertile with reduced sperm production [223, 
224]. Additionally these mice develop skin hyperpigmentation, increased intestinal 
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apoptosis, and pancytopenia. This phenotype is reminiscent of the human progeroid 
syndrome dyskeratosis congenita (reviewed in [226]). Combination of Pot1b deficiency 
and telomerase haploinsufficiency, as described for MEFs above, resulted in a significant 
worsening of all aspects of the Pot1b-deficient phenotype and in eventual death of these 
mice due to bone marrow failure. The role of shelterin proteins in models of bone marrow 
failure will be discussed in detail below. Complete loss of telomerase activity in the 
setting of Pot1b deficiency resulted in embryonic lethality, perhaps due to excessive 
chromosomal shortening during early development. 
Tpp1 
Pot1 binding requires Tpp1, the protein product of the Acd gene [172, 214-217]. 
Studies in Acd-/- MEFs have indeed revealed that many elements of the Acd-deficient 
phenotype reproduced those observed when Pot1a/b were deleted, predominantly 
identifying suppression of ATR signaling and HR through Pot1a/b as the principle 
function of Tpp1 [215]. Additional studies, however, have implicated Tpp1 in a more 
complex role in end protection. Two groups have identified NHEJ-type chromosomal 
fusions and not just homologous recombination events in the setting of Acd deficiency, 
suggesting protective functions for Tpp1 beyond Pot1a/b recruitment [172, 227]. This is 
perhaps due to the triggering of an alternative NHEJ pathway that has been described to 
be activated at telomeres when Pot1a/b are lost [187]. Using a knockdown approach (as 
opposed to the null allele approach used in [215]), it was demonstrated that Tpp1 loss 
resulted in an ATM-dependent DNA damage response, compared to an ATR dependent 
DNA damage response following Pot1a/b knockdown [172]. An additional report 
demonstrated that Tpp1 loss in MEFs through a conditional inactivation strategy resulted 
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in activation of both ATM- and an ATR-mediated DNA damage responses [228]. The 
reason for the differences in the specific nature of the DDR identified between these 
studies is unclear, though the use of different models of Acd inactivation (genetic deletion 
vs. knockdown vs. deletion of the Pot1a/b interacting domain), differences in allelic 
targeting strategies in Acd knockout generation, or variations in DDR detection strategies 
could be responsible for these differences. Regardless, these studies demonstrated that 
Tpp1 played a critical role in telomeric end protection. 
Acd deletion ultimately resulted in p53-mediated growth arrest in MEFs [172, 
228]. In these studies, p53 inactivation significantly improved Acd-deficient MEF cell 
cycle activity. Additional work demonstrated that there might also be p53-independent 
factors contributing to Acd-deficient MEF growth arrest [215]. In this work, MEFs that 
had been immortalized through SV40 large T antigen, which inactivates both p53 and the 
tumor suppressor retinoblastoma (Rb), still showed signs of growth arrest. Together, 
these data demonstrated that p53-depenedent and independent factors contributed to 
growth arrest and eventual senescence when Acd was inactivated. 
In addition to being essential for protection from the DDR, Tpp1 plays a 
multidimensional role in regulating telomerase activity at the telomeric end. Initial work 
in a human cell lines demonstrated that TPP1 was required for the recruitment of 
telomerase to the telomeric end [229]. This telomerase recruitment activity was attributed 
to the oligonucleotide/oligosaccharide binding (OB) fold domain of TPP1. Recent studies 
identified that a small region in the TPP1 OB fold, termed the TEL patch, was both 
necessary and sufficient for this telomerase recruitment [230, 231]. This suggests that 
TPP1 may be required not just for DDR suppression, but also for telomere elongation in 
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telomerase-expressing cell types, including embryonic and somatic stem cells and cancer 
cells. 
In addition to telomerase recruitment, TPP1 promotes telomerase processivity 
[232]. In vitro biochemical analysis demonstrated that the presence of TPP1 increases the 
efficiency with which telomerase extends telomeres. Recent work identified that this 
activity is tractable to the TEL patch of the OB fold. Thus, the OB fold was linked to both 
telomerase recruitment and the efficiency of telomerase activity in extending telomeres. 
A recent study has identified that TPP1 interacts with the CST complex to limit 
excessive telomere elongation [233]. This study proposed a model in which the CST 
complex is in competition with TPP1/POT1 during telomere elongation. At early steps of 
telomere replication, TPP1 recruits telomerase and promotes telomere extension, as 
described above. As replication progresses, CST binds the elongating 3’ G-strand, 
preventing further association between telomerase and the G-strand. Additionally, the 
presence of CST inhibits the ability of TPP1 to enhance telomerase processivity. The 
authors of this study suggested that CST present at the telomere could promote 5’ strand 
fill-in (discussed above), but did not directly test this phenomenon. This study 
demonstrated the complex role that TPP1 plays in telomere length homeostasis. 
Given the complex role that Tpp1 plays in telomere length homeostasis and DDR 
repression, it was not surprising that complete Acd inactivation results in embryonic 
lethality [215]. Studies using a spontaneously occurring Acd splice variant that results in 
a hypomorphic acd allele demonstrated several essential development functions for Acd 
[234]. Depending on the mouse strain to which the allele was bred, mice homozygous for 
acd displayed adrenocortical dysplasia, caudal truncation, genitourinary abnormalities, 
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skin hyperpigmentation, and significant strain-dependent embryonic or perinatal lethality. 
Interestingly, a subsequent study reported that conditional inactivation of Acd in the skin 
resulted in profound hyperpigmentation and eventual mortality due to the loss of skin 
barrier function [228]. In both skin-specific Acd deletion and acd homozygous mice, the 
majority of the phenotypic abnormalities could be rescued by p53 inactivation [228, 235, 
236]. Interestingly, p53 inactivation failed to rescue strain-specific embryonic mortality 
in acd homozygotes [235]. Together, these data suggested that Tpp1 plays critical roles in 
mammalian development, and that, as was true in MEF studies, these processes are 
mediated by p53-dependent and independent mechanisms. 
Tin2 
Tin2 is an adaptor protein that plays critical roles in stabilizing the shelterin 
complex. Within the shelterin complex, Tin2 binds both Trf1 and Trf2 and stabilizes 
Trf1/Trf2 binding to telomeres [237]. Tin2 also binds Tpp1 and is required for 
Tpp1/Pot1a/b recruitment to the shelterin complex [238]. Loss of Tin2 results in ATR 
activation, due to the loss of Tpp1/Pot1a, excessive 3’ overhang generation, due to loss of 
Tpp1/Pot1b, and ATM activation, due to Trf2 destabilization. These data highlight the 
critical function of Tin2 in organizing the shelterin complex. 
TIN2 has additional roles outside of telomere homeostasis. TIN2 was detected in 
the mitochondria in a human cancer cell line, and TIN2 knockdown resulted in the 
adoption of abnormal mitochondrial morphology [239]. TIN2 loss promoted increased 
oxidative metabolism and reduced glycolysis in these human cancer cells. These data 
demonstrate that TIN2 has telomeric and extratelomeric functions, and suggest the 
possibility that other shelterin components may function away from the telomere. 
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Tin2 loss causes embryonic lethality in mice [240]. Conditional inactivation of 
Tin2 has not been characterized in vivo. However, TIN2 mutations were identified in a 
cohort of human patients with dyskeratosis congenita [241-244]. These findings are 
discussed below, but indicated that TIN2 indeed plays a critical role in telomere 
homeostasis in vivo. 
THE SHELTERIN COMPLEX AND BONE MARROW FAILURE  
Perhaps the best demonstration of the significance of the shelterin complex in 
bone marrow failure has come from studies of dyskeratosis congenital (DKC). DKC is a 
human telomere shortening syndrome that has been linked to mutations in TERC 
(telomerase RNA), TERT (telomerase protein), DKC1 (encoding dyskerin, an accessory 
protein required for TERC stability and function), and recently in TIN2 (reviewed in 
[245]). Patients classically present with the triad of oral leukoplakia, abnormal skin 
pigmentation, and nail abnormalities. Up to 85% of these patients develop bone marrow 
failure with a variable timeline, thus establishing the need to consider DKC in the context 
of hematopoiesis [226]. It is estimated that up to 60% of DKC cases do not have a known 
underlying genetic defect [246].  This suggests that our knowledge of the genetic causes 
of DKC remains limited, and additional contributing genes must be considered. 
Mutations in TIN2 identify a unique class of DKC patients. Genetic analysis 
identified a mutation near the region of TIN2 that interacts with TRF1 [247]. Based on 
studies described above, such a mutation could greatly destabilize the shelterin complex 
and elicit a robust DDR. These patients had a particularly severe form of DKC 
characterized by early symptom onset with broad organ involvement, and an increased 
incidence of bone marrow failure [243]. At least two reports documented that these 
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findings are associated with more severe telomere shortening than other DKC forms 
[242, 244]. Since TIN2 disruption could result in TPP1/POT1loss and TRF1/TRF2 
destabilization, this may induce a robust DDR activation and consequent telomere 
attrition due to deprotection. DKC arising from TERC or TERT dysfunction, on the other 
hand, would result in progressive telomere erosion as highly replicative tissues turn over. 
The differences between these models would predict that TIN2 mutations would result in 
a more acute and perhaps widespread form of DKC, while TERC/TERT mutations would 
result in a more progressive and perhaps localized form of DKC. The possibility that 
other shelterin components could similarly contribute to human DKC has yet to be 
evaluated. 
HSCs from human DKC patients with TERC mutations showed that defective 
self-renewal could significantly contribute to bone marrow failure in DKC [248]. HSC 
recovery from DKC patients was significantly reduced, but differentiation ability was not 
impaired in short-term culture. Strikingly, HSC self-renewal assessment in long-term 
cultures showed severe self-renewal defects and advanced telomere shortening. Together, 
these data demonstrated that bone marrow failure in DKC patients is not due to defective 
differentiation, but is instead a direct result of impaired HSC self-renewal. The link 
between HSC dysfunction and bone marrow failure in other forms of DKC has not been 
evaluated. 
MOUSE MODELS OF DKC 
   Mouse models of Trf1, Pot1b, Acd, and Rap1 deficiency, along with Trf2 
overexpression all resulted in skin hyperpigmentation [196, 202, 210, 223, 224, 228, 234, 
236]. This was reminiscent of classical skin pigmentation abnormalities described in 
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DKC patients. This similarity prompted the further assessment of the extent to which 
models of shelterin deficiency recapitulate pathologies associated with human DKC. Of 
significant interest was whether or not these models reproduce the primary cause of DKC 
mortality: bone marrow failure. 
The first mouse models of DKC developed from observations of aforementioned 
mice in which Pot1b deficiency was combined with Terc haploinsufficiency [223, 224]. 
In addition to skin hyperpigmentation, these mice displayed progressive testicular 
atrophy, increased apoptosis in intestinal crypts, and reduced lifespan in the context of 
telomere shortening. Reduced life expectancy was attributed to the development of severe 
pancytopenia and bone marrow failure. This was significant for being the first 
demonstration of a progressive bone marrow failure in the setting of shelterin disruption, 
and thus the first evidence that studies in shelterin could provide models to understand 
DKC pathophysiology. 
It remained to be determined if bone marrow failure in the Pot1b-/-Terc+/- model 
could be linked to HSC failure. It was possible that progressive telomere shortening 
resulted in defective differentiation of HSCs to mature cell types, or that shortened 
telomeres triggered apoptosis in differentiating progenitors as opposed to HSCs. Recent 
work revealed that significant HSC self-renewal defects were the main cause of bone 
marrow failure [60]. Pot1b-/-Terc+/- HSCs were reduced in number and failed to compete 
in bone marrow transplantation assays. Hematopoietic progenitor cells had increased p53 
activation with a bias towards an apoptotic response rather than cell cycle arrest. Of 
particular significance, p53 inactivation significantly rescued HSC function, 
demonstrating that p53 played a critical role in reduced Pot1b-/-Terc+/- HSC function. 
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A recent model of Trf1 deficiency further demonstrated the significance of 
shelterin in models of DKC [59]. Trf1 deletion resulted in a progression to bone marrow 
failure within 3 weeks of deletion. Trf1-/- HSCs had impaired self-renewal activity in 
transplantation assays. Bone marrow failure did not occur in conjunction with increased 
apoptosis, but significant p21 up-regulation suggested a role for p53 activation in this 
model. The role of p53 activation in limiting HSC self-renewal was not tested. Of 
significance in this study, bone marrow failure was described as occurring in the context 
of telomere shortening and increased senescence during long-term studies. The authors of 
this study did not address if remaining hematopoietic progenitors at these late time points 
were in fact Trf1-/- or if they represented cells that had escaped Cre-mediated deletion. If 
relatively few cells escaped and reconstituted hematopoiesis, these HSCs would be 
exceptionally stressed and could display telomere shortening and increased senescence as 
a result. This is an important point to resolve experimentally. 
Thus, shelterin-based studies revealed two complementary, but significantly 
different models of DKC and bone marrow failure. Pot1b-/-Terc+/- resulted in a 
progressive bone marrow failure that demonstrated cooperativity between shelterin and 
telomerase in regulating HSC self-renewal. Trf1 loss resulted in bone marrow failure that 
was caused by acute HSC dysfunction. Since this study did not require additional 
telomerase dysfunction, it suggested that certain shelterin components are uniquely 
capable of destabilizing telomere homeostasis in a timeline not consistent with telomere 
erosion. This is not a concept that has been rigorously tested in vivo, though the data 
indicate that it ought to be, as human patients with TIN2 mutations progress to bone 
marrow failure in a more acute timeline than is observed with other known DKC 
	   79	  
mutations. Therefore, similar to studies in MEFs and cell lines, individual shelterin 
proteins must be evaluated for their roles in the maintenance of HSC function as it relates 
to bone marrow failure. 
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CHAPTER 5.  MURINE HEMATOPOIETIC STEM CELLS ARE 
ACUTELY SENSITIVE TO INACTIVATION OF THE SHELTERIN 
GENE ACD 
* 
ABSTRACT 
The shelterin complex plays dual functions in telomere homeostasis by recruiting 
telomerase and preventing activation of a DNA damage response. Somatic stem cells 
require telomerase activity, as evidenced by progressive stem cell loss in hereditary 
dyskeratosis congenita. Recent work demonstrates that dyskeratosis congenita can also 
arise from mutations in specific shelterin genes, although little is known about shelterin 
functions in somatic stem cells. Here, we report that hematopoietic stem cells (HSCs) are 
acutely sensitive to inactivation of the shelterin gene Acd, encoding Tpp1. Homozygosity 
for a hypomorphic Acd allele led to profoundly defective fetal HSCs. Upon complete Acd 
inactivation, HSCs expressed p53 target genes, underwent cell cycle arrest and were 
severely depleted within days, leading to hematopoietic failure. Tpp1 loss induced 
increased telomeric fusion events. However, unlike in epidermal stem cells, p53 
inactivation did not rescue Tpp1-deficient HSCs, indicating that shelterin dysfunction has 
unique effects in different stem cell populations. Because consequences of telomere 
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shortening are progressive and unsynchronized, acute loss of shelterin function represents 
an attractive alternative to study telomere crisis in hematopoietic progenitors. 
INTRODUCTION 
Linear chromosomes are capped with telomeres to protect their ends from the loss of 
genetic material during strand replication. Disruptions in the stability of this molecular 
buffer have been linked to organ failure, aging and cancer. Privileged compartments, 
including the germline and somatic stem cells, express the ribonucleoprotein telomerase 
to maintain telomere length during replicative stress [53, 167]. When this activity is 
impaired, stem cell populations become depleted, leading to loss of tissue homeostasis 
[56]. In addition, telomeres must be protected from the DNA damage response that would 
perceive telomeres as sites of DNA breaks, a function achieved by the shelterin complex. 
Together, the six shelterin proteins Trf1, Trf2, Rap1, Tin2, Pot1 and Tpp1 not only 
protect telomeres, but also recruit and regulate telomerase activity [171]. Understanding 
the biological functions of these proteins is therefore critical to understanding telomere 
homeostasis and human diseases related to dysfunctional telomeres. 
Studies using murine embryonic fibroblasts showed that individual shelterin proteins 
have specific functions in suppression of the DNA damage response and telomere 
regulation. Pot1 binds the single-stranded telomeric overhang and prevents ataxia 
telangectasia and Rad3-related (ATR) kinase activation [172, 173]. Pot1 binding requires 
Tpp1, the protein product of the Acd gene [172, 214, 215]. In addition to being essential 
for Pot1 recruitment, Tpp1 recruits telomerase to the telomeric end and is required for 
telomere extension [229, 232]. Trf1 and Trf2 bind the double-stranded portion of the 
telomere [189-191]. Trf2 prevents ataxia telangectasia mutated (ATM) kinase from 
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mistaking telomeric ends for sites of DNA breaks [173, 249]. Tin2 stabilizes Trf1 and 
Trf2 at the telomere and binds to Tpp1, linking the single-stranded and double-stranded 
binding portions of shelterin [237, 238]. Rap1 interacts with Trf2 and prevents aberrant 
non-homologous end joining from occurring at the telomere [206-208]. In mice, studies 
of the shelterin complex are complicated by the duplication of the Pot1 gene into Pot1a 
and Pot1b [221]. Pot1a prevents ATR activation and Pot1b prevents excessive 5’ 
resection at the telomere and consequent generation of excessive 3’ overhangs [221]. In 
humans, a single POT1 protein accomplishes both of these functions [218]. To obtain 
complete loss of Pot1 function in mice, either Pot1a/b double deficient mice must be 
used, or Acd must be inactivated. In embryonic fibroblasts, both Acd inactivation and 
Pot1a/b deletion caused rare telomeric fusion events and proliferative arrest, a phenotype 
that required p53-driven expression of the cyclin-dependent kinase inhibitor p21 [172, 
214, 215, 221]. 
Although embryonic fibroblasts have been a useful tool in understanding the 
molecular functions of the shelterin complex in cell culture systems, the physiological 
role of shelterin components in vivo remains poorly understood, especially in tissues 
maintained by somatic stem cells. Recent studies demonstrated that when combined with 
telomerase haploinsufficiency, Pot1b deficiency resulted in a gradual decline in tissue 
homeostasis similar to that observed in late generation telomerase-deficient mice [224]. 
These mice displayed skin hyperpigmentation and bone marrow failure reminiscent of 
human patients with the telomere shortening syndrome dyskeratosis congenita (DKC). 
DKC has been linked to mutations in the telomerase components genes TERC and TERT, 
or in DKC1, encoding the telomerase accessory protein dyskerin [250]. Recently, 
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mutations affecting the shelterin gene TIN2 have been identified in patients with a 
particularly aggressive form of the disease [241-244]. As HSC loss leading to bone 
marrow failure is the most frequent cause of lethality in DKC, understanding the 
importance of telomerase and shelterin genes in hematopoiesis is relevant to human 
disease. Mice deficient for Acd due to homozygosity for a spontaneously arising 
hypomorphic acd allele demonstrate a pleiotrophic phenotype that includes 
adrenocortical dysplasia, caudal truncation, genitourinary abnormalities, skin 
hyperpigmentation, and significant strain-dependent embryonic or perinatal lethality 
[234]. These data indicate tissue-specific functions of Tpp1. Furthermore, the skin 
hyperpigmentation phenotype observed in Acd-deficient mice bares a striking similarity 
to that observed in DKC patients and in the Pot1b-deficient mouse model. Subsequent 
studies using complete loss of Acd in a skin-specific knockout model indicated that the 
hyperpigmentation phenotype resulted from functional defects in epidermal stem cells, 
suggesting a role for shelterin components in stem cell maintenance in this compartment 
[228]. In both the complete knockout and hypomorphic Acd models, defects were linked 
to telomere dysfunction as well as p53-mediated apoptosis and proliferative arrest [228, 
235, 236]. 
To gain detailed insight into functions of the shelterin complex in hematopoiesis, we 
studied the impact of Acd deficiency on hematopoietic stem cells (HSCs). By targeting 
Acd, we focused on a central component of the shelterin complex that is essential for 
Pot1a/b function and plays a role in telomerase recruitment. Our approach was designed 
to capture both acute and long-lasting effects of Acd deficiency on hematopoietic stem 
and progenitor cells. We found that stem cell function was profoundly dependent on 
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Tpp1 in both fetal and adult hematopoiesis. In mice homozygous for a hypomorphic Acd 
allele, hematopoietic stem and progenitors were generated and maintained during fetal 
life, but they acquired phenotypic abnormalities, evidence of G2/M arrest and a complete 
inability to reconstitute irradiated recipients after transplantation, indicating defective 
function. In the complete absence of Acd, HSCs were rapidly depleted and animals 
progressed to frank hematopoietic failure. This phenotype was cell-autonomous and 
surprisingly acute, as a complete depletion of the hematopoietic stem and progenitor 
compartment was observed within 5 days after Acd inactivation. Tpp1 loss led to rapid 
induction of p53 target gene expression. However, p53 inactivation failed to rescue HSC 
depletion and function. These findings differed markedly from past observations on 
hematopoiesis in Pot1b-deficient mice as well as organ development in Acd hypomorphic 
mice and skin stem cell function in the absence of Acd, as all these phenotypes were 
largely rescued by p53 deficiency. Thus, our data identify an essential acute requirement 
for Acd in hematopoietic stem and progenitor cells that differs from its effects in other 
tissues and stem cell compartments. 
RESULTS 
Acd deficiency results in cell cycle arrest and impaired function of fetal liver 
hematopoietic stem cells.  
To assess the role of Acd in hematopoiesis, we first used mice that were 
homozygous for a spontaneously occurring hypomorphic allele [234]. This hypomorphic 
Acd variant is caused by a G to A transition within the third intron of the gene (Figure 
5.1A), resulting in aberrant splicing and either a 7bp insertion after exon 3 or the 
inclusion of the entire third intron in the mRNA [227, 234]. Both outcomes cause 
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premature termination of translation and a truncated protein lacking all functional 
domains. Homozygosity for this allele (henceforth acd) decreases expression of wild-type 
transcripts to ~2% of normal, consistent with a profoundly hypomorphic phenotype 
[227]. Analysis of the fetal livers from E13.5 acd mice revealed an overall mild decrease 
in fetal liver cellularity compared to control littermates (Figure 5.1B). Of note, acd 
fetuses also had a reduction in body weight (data not shown). When cell numbers were 
normalized in colony forming assays measuring hematopoietic progenitor activity, no 
defect in the ability of acd fetal liver cells to form myeloid colonies was observed 
(Figure 5.1C). Flow cytometric analysis revealed that acd fetuses had a normal 
frequency of Lineage– fetal liver cells and an increased frequency of Lineage–Sca-
1+cKithi (LSK) cells, containing hematopoietic progenitors (Figure 5.1D). Furthermore, 
acd hypomorphism did not cause a significant defect in the overall frequency of 
CD150+CD48- LSK cells, the most rigorous phenotypic definition of long-term 
hematopoietic stem cells (HSCs) [156, 157] (Figure 5.1D). Thus, HSC frequencies and 
myeloid progenitor activity were not compromised in acd animals. However, close 
analysis of the LSK progenitor compartment (containing HSCs) revealed that acd LSKs 
were larger, more granular, and expressed higher levels of the surface protein Sca-1, 
suggesting an activated phenotype (Figure 5.1E). Cell cycle analysis demonstrated an 
accumulation of acd progenitors at the G2/M phases of the cell cycle (Figure 5.1F). This 
phenotype was reminiscent of the G2/M arrest reported in Acd-deficient embryonic 
fibroblasts and epidermal progenitor cells [215, 228]. 
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Figure 5.1. Reduced Acd expression results in phenotypic abnormalities and G2/M arrest in fetal 
hematopoietic progenitors. (A) Structure of the hypomorphic acd allele, a mutant Acd allele arising from 
an intron 3 G→A transition and leading to aberrant splicing. acd homozygosity decreased the abundance of 
normal transcripts to ~2% of wild-type (WT) (33); (B) Fetal liver cellularity in E13.5 mice homozygous for 
the acd hypomorphic allele; (C) CFU-GM analysis demonstrating preserved granulocyte-macrophage 
(GM) progenitor activity in E13.5 acd fetal liver (representative of 3 experiments with triplicate colony 
formation assays, mean +/-SEM); (D) Preserved overall frequency of phenotypically defined long term 
hematopoietic stem cells (LT-HSCs), defined as CD150+CD48– Lin–Scahic-Kithi (LSK) cells (n>9 
mice/group from 5 independent experiments, mean +/- SEM); (E) Increased Sca-1 expression in acd LSK 
progenitors. acd LSK cells were also larger and more granular by forward (FSC-A) and side scatter (SSC-
A) characteristics, respectively (n>9 mice/group from 5 independent experiments). Gray shading shows 
data from control littermates, white shading represents acd progenitors. MFI: mean fluorescence intensity; 
(F) Cell cycle analysis with BrdU incorporation (12 hour pulse) and intracellular DAPI staining for 
(icDAPI, DNA content) in E13.5 acd Lin–c-Kithi hematopoietic progenitors, showing accumulation in 
G2/M phases of the cell cycle (n=3 mice/group from 3 independent experiments, mean +/- SD). 
Representative flow cytometry plots are shown. Numbers indicate the percentage of cells in each gate. 
*p<0.05, **p<0.01, ***p<0.001. 
Although colony formation assays measure the output of a heterogeneous 
progenitor pool, they do not evaluate HSC self-renewal. To study the function of acd 
fetal HSCs, we performed competitive transplantation assays in lethally irradiated 
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recipients and followed transplanted animals to monitor long-term reconstitution (Figure 
5.2A). We observed profound defects in trilineage reconstitution from acd fetal 
progenitors as early as 4 weeks post-transplant that persisted for the duration of the 
experiment (Figure 5.2B). When the LSK compartment of primitive hematopoietic 
progenitors was examined at the termination of the experiment, no contribution of acd 
cells could be detected (Figure 5.2C). These findings demonstrate that, despite preserved 
hematopoietic progenitor frequencies and myeloid progenitor activity, acd HSCs had 
severe functional impairment. 
	  
Figure 5.2. acd hematopoietic stem cells do not support long-term hematopoietic reconstitution. (A) 
Experimental design: lethally irradiated B6-CD45.1 mice were transplanted with 1:1 mixtures of E13.5 
wild-type (WT) fetal liver (CD45.2+) or E13.5 acd hypomorphic fetal liver (CD45.2+) and B6-CD45.1 
competitor bone marrow cells (5x105 cells each); (B) Flow cytometric analysis of peripheral blood 4-16 
weeks after transplantation showing robust contribution of the wild-type but not acd CD45.2+ fetal liver 
graft to myeloid (CD11b+Gr1+), T cell (CD3+) and B cell compartments (CD19+B220+) (n=3-5/group, mean 
+/– SD); (C) CD45.1/CD45.2 chimerism in Lin–Scahic-Kithi (LSK) bone marrow progenitors 16 weeks after 
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transplantation. No residual CD45.2+ acd progenitors could be detected. Representative flow cytometry 
plots are shown. Numbers indicate the percentage of cells in each gate. Graphs show mean +/ – SEM. 
*p<0.05, **p<0.01, ***p<0.001. 
Acd inactivation leads to acute depletion of adult hematopoietic stem and progenitor 
cells.  
Analysis of the acd phenotype revealed profound HSC functional defects, but 
non-hematopoietic developmental abnormalities in acd fetuses could have contributed to 
these defects through non-cell-autonomous mechanisms. Furthermore, analysis of a 
hypomorphic phenotype may underestimate the full impact of Acd given the presence of 
residual wild-type transcripts at low levels. To bypass these limitations, we studied the 
effects of complete Acd inactivation in adult hematopoietic tissues using a conditional 
Acd allele that we previously described [215] (Figure 5.3A). This strategy facilitated 
robust, temporally controlled Acd excision in hematopoietic cells, and thus allowed us to 
study the acute effects of Tpp1 loss in hematopoietic tissues. We induced Acd 
inactivation using poly(I:C) injections to activate the interferon-responsive Mx-Cre 
transgene [251] (Figure 5.3A, B). Within 48 hours of a single poly(I:C) injection, we 
achieved at least 80% excision of the floxed Acd allele (Figure 5.3C). Within 5 days, we 
found that the hematopoietic progenitor compartment in Acdfl/– animals became severely 
depleted (Figure 5.3D), and we could already detect a reduction in total bone marrow 
cellularity (Figure 5.3E). These data indicate that hematopoietic tissues are acutely 
sensitive to Acd inactivation, and that this sensitivity can be traced back to a rapidly 
failing hematopoietic progenitor compartment. 
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Figure 5.3. Acute depletion of adult hematopoietic progenitors after Acd inactivation. (A) Structure of 
the floxed Acd allele with loxP sites flanking exons 3-8 (Acdfl). Mx-Cre expression was achieved via 
poly(I:C) injections, leading to Acd inactivation into an excised null allele (Acd–). Arrows indicate p2 and 
p7 primer pairs used to quantify excision efficiency; (B) Experimental timeline to capture the acute effects 
of Acd inactivation; (C) Quantitative PCR for Acd exon 7 (p7) relative to exon2 (p2) DNA in Lin–Scahic-
Kithi (LSK) progenitors, demonstrating ~80% excision of the floxed region after only a single poly(I:C) 
injection (qPCR; data are shown as mean ± SEM and are representative of 3 individual mice per group); 
(D) Flow cytometric analysis of hematopoietic progenitors at day 5 after poly(I:C), showing profound 
depletion of LSK progenitors and decreased bone marrow (BM) cellularity (Acd+/– n=5; Acdfl/– n=4). 
Representative flow cytometry plots are shown. Numbers indicate the percentage of cells in each gate. 
**p<0.01. 
The type I interferon response resulting from poly(I:C) administration was 
previously shown to drive quiescent HSCs into the cell cycle, which could enhance the 
impact of Tpp1 loss in hematopoietic progenitors [83]. To avoid this problem, we bred 
CreERT2 x Acdfl/– mice and inactivated Acd with tamoxifen [252] (Figure 5.4A). We 
observed decreased c-Kit expression at day 3 and near disappearance of LSK 
hematopoietic progenitors at day 5 after starting tamoxifen administration in CreERT2 x 
Acdfl/– mice (Figure 5.4B, C).  These findings indicate that primitive hematopoietic 
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progenitors are acutely sensitive to Tpp1 loss even in the absence of an interferon 
response. 
 
	  
Figure 5.4. Acd inactivation with tamoxifen-inducible Cre recombinase results in rapid depletion of 
hematopoietic stem and progenitor cells. (A) Experimental design: tamoxifen was administered to 
control Cre-ERT2+ x Acd+/– or Cre-ERT2+ x Acdfl/– mice (1 mg i.p. daily day 1-3). The Cre-ERT2 
lentitransgene encodes the ubiquitously expressed Tamoxifen-inducible Cre-ERT2 recombinase; (B-C) 
Flow cytometric analysis of bone marrow at day 3 (B) or day 5 (C) after initiation of tamoxifen. In Cre-
ERT2+ x Acdfl/– mice, the Lineage–Sca-1+cKithi (LSK) compartment (containing hematopoietic stem and 
progenitors cells) became abnormal within 3 days of tamoxifen administration and was severely depleted 
within 5 days. Representative flow cytometry plots are shown. Numbers indicate the percentage of cells in 
each gate. 
Cell-autonomous mechanisms underlie the requirement for Acd in hematopoiesis.  
Although Mx-Cre is primarily expressed in the bone marrow, activity can also be 
detected in other organs such as liver, kidney and skin. Thus, non-cell autonomous 
mechanisms could still contribute to hematopoietic defects in Mx-Cre+ x Acdfl/– mice. To 
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exclude this possibility, we generated bone marrow chimeras and studied Acd/Tpp1-
deficient hematopoiesis in a wild-type environment. Lethally irradiated B6-CD45.1 mice 
were transplanted with Mx-Cre+ x Acdfl/– or control Mx-Cre+ x Acd+/– bone marrow, 
allowing 6 weeks for full hematopoietic reconstitution before poly(I:C) injection (Figure 
5.5A). To examine the effects of Acd inactivation on overall hematopoiesis, we 
monitored peripheral blood counts of transplant recipients for 20 weeks following 
poly(I:C) administration (Figure 5.5B). Tpp1 loss led to significant pancytopenia 
between weeks 1 and 4 after starting poly(I:C). Subsequent analysis showed recovery of 
peripheral blood counts by ~6 weeks. At week 20, bone marrow cellularity and LT-HSC 
numbers in Mx-Cre+ x Acdfl/– recipients had recovered to numbers similar as those in 
control bone marrow chimeras (Figure 5.5C). To identify the source of this 
reconstitution, bone marrow was plated in methylcellulose cultures and individual 
colonies were harvested for clonal evaluation of Acd inactivation. All colonies analyzed 
maintained the floxed allele, demonstrating that reconstitution in Mx-Cre+ x Acdfl/– 
recipients had occurred exclusively from cells that escaped Cre-mediated gene deletion 
(Figure 5.5D). 
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Figure 5.5. Hematopoietic inactivation of Acd in a wild-type environment results in pancytopenia 
followed by strong selection for reconstitution by unexcised progenitors. (A) Experimental design: 
lethally irradiated B6-CD45.1 mice were transplanted with Mx-Cre+Acd+/– or Mx-Cre+Acdfl/– bone marrow 
(BM) cells (5x105). Six weeks later, poly(I:C) was administered to induce Acd/Tpp1 inactivation only in 
donor-derived hematopoietic cells; (B) Complete blood counts at baseline and 1-20 weeks after poly(I:C) 
injection, showing a transient reduction in platelet, lymphocyte and neutrophil counts (mean +/- SD); (C) 
Flow cytometric analysis of Lin–Scahic-Kithi (LSK) progenitors and long-term hematopoietic stem cells 
(LT-HSCs) at 20 weeks after poly(I:C) injection, revealing no difference in HSC frequency and BM 
cellularity of Mx-Cre+Acd+/– and Mx-Cre+Acdfl/– recipients (Acd+/– n=5; Acdfl/– n=3, mean +/- SEM). 
Representative flow cytometry plots are shown. Numbers indicate the percentage of cells in each gate; (D) 
Clonal analysis of hematopoietic progenitors by CFU-GM and single colony PCR at week 20. In Mx-
Cre+Acdfl/– recipients, all colonies analyzed (28/28) retained the Acdfl allele and had thus escaped Mx-Cre-
mediated Acd inactivation. Representative PCR results are shown. 
In view of the strong selection pressure favoring cells that preserved an undeleted 
Acd allele, we generated competitive bone marrow chimeras in which CD45.2+ Mx-Cre+ 
x Acdfl/– bone marrow could be studied in the presence of CD45.1+ wild-type competitors 
(Figure 5.6A). This strategy decreased the selection pressure favoring rare Mx-Cre+ x 
Acdfl/– progenitors escaping Acd inactivation, as hematopoiesis was maintained by 
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CD45.1+ competitor cells throughout the experiment. Bone marrow chimeras were given 
6 weeks to facilitate recovery of baseline hematopoiesis prior to Acd deletion. Within 4 
weeks of poly(I:C) administration, no contribution from the Acd-deficient CD45.2+ graft 
could be detected among blood myeloid cells, a population characterized by its rapid 
turnover (Figure 5.6B). Peripheral blood B and T cells arising from the Acd-deficient 
graft also became progressively depleted (Figure 5.6C). This trilineage defect suggested 
failure of multipotent stem and progenitor cells. Indeed, no residual Acd-deficient HSCs 
could be detected in the bone marrow at the termination of the experiment (Figure 5.6D). 
Altogether, these data demonstrate that Acd is cell-autonomously required by HSCs, with 
strong selective pressure for rare progenitors that maintain a functional Acd gene to 
support hematopoietic recovery. 
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Figure 5.6. Acd-deficient HSCs do not support hematopoiesis after competitive bone marrow 
transplantation. (A) Experimental design: lethally irradiated B6-CD45.1 mice were transplanted with 1:1 
mixtures of Mx-Cre+Acd+/– or Mx-Cre+Acdfl/– and competitor B6-CD45.1 bone marrow (BM) cells (5x105 
each). After 6 weeks to allow hematopoietic reconstitution, baseline chimerism was assessed, followed by 
poly(I:C) administration; (B) Flow cytometric analysis of CD45.2/CD45.1 chimerism among CD11b+Gr1+ 
blood myeloid cells at baseline (Wk0) and 4 weeks after poly(I:C) (Wk4). Representative flow cytometry 
plots are shown (n=5 mice per group, 2 independent experiments); (C) Flow cytometric analysis of 
peripheral blood 0-16 weeks after poly(I:C), showing a rapid drop in contribution of the CD45.2+ Acdfl/– 
graft to the myeloid (CD11b+Gr1+), T cell (CD3+), and B cell (CD19+B220+) compartments (mean +/- 
SEM, 2 independent experiments); (D) CD45.2/CD45.1 chimerism in the long-term hematopoietic stem 
cell (LT-HSC) compartment 16 weeks after poly(I:C) administration, revealing no residual CD45.2+ Acdfl/– 
HSCs. Representative flow cytometry plots are shown (n=5 mice/group). Numbers indicate the percentage 
of cells in each gate. 
Deletion of Acd in fetal liver hematopoietic stem and progenitor cells results in 
hematopoietic failure and death.  
Fetal and adult HSCs have numerous differences with respect to gene expression 
programs, cytokine responsiveness and cell cycle activity. Thus, it was possible that adult 
and fetal HSCs had different sensitivities to complete Acd inactivation. To address this 
question, we bred Acdfl/fl mice with Vav-Cre transgenic mice (Figure 5.7A). Previous 
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studies have demonstrated that Vav-Cre is expressed specifically in fetal hematopoietic 
cells starting at ~E10.5, leading to near complete excision of target loci by day E14.5 [21, 
253]. No Vav-Cre+ x Acdfl/fl mice were born, while other genotypes were present at the 
expected mendelian frequency (Fig. 5.7B). At E14.5, live Vav-cre+ x Acdfl/fl fetuses were 
present, but these mice had pale fetal livers and vasculature, suggesting defective 
hematopoiesis (Fig. 5.7C, D). Flow cytometric analysis revealed that fetuses with 
hematopoietic-specific Acd inactivation had few if any residual hematopoietic LSK 
progenitors in the liver at E14.5 (Figure 5.7E). These data demonstrate that maintenance 
of both fetal and adult HSCs is acutely dependent on Acd. 
 
	  
Figure 5.7. Complete Acd inactivation in fetal hematopoietic cells is incompatible with survival. (A) 
Experimental design: Acd inactivation restricted to fetal hematopoiesis was achieved using a Vav-Cre+ 
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transgene. Breedings were established using Vav-Cre+Acdfl/+ parents; (B) Genotyping results demonstrating 
that no Vav-cre+Acdfl/fl were born, while all other genotypes were represented. Genotyping results varied 
significantly from Mendelian predictions by Chi Squared analysis (p=1.60x10-5); (C-D) At E14.5, live Vav-
cre+Acdfl/fl fetuses could be identified, however these mice were pale compared to all other genotypes.  No 
difference was detected between observed genotypes and those predicted by Mendelian ratios (p=0.19); (E) 
Flow cytometric analysis of E14.5 fetal livers, demonstrating that Vav-cre+Acdfl/fl fetuses had profoundly 
depleted Lineage–Sca-1+cKithi (LSK) hematopoietic progenitors. Representative flow cytometry plots are 
shown. Numbers indicate the percentage of cells in each gate.  
Acd deficiency results in acute p53 activation, but p53-independent cell cycle arrest in 
hematopoietic progenitors.  
Based on work in other cell types such as embryonic fibroblasts and epidermal 
stem cells, Acd inactivation is predicted to activate a DNA damage response due to the 
loss of Pot1 localization at telomeric ends, with many downstream effects driven by p53 
activation. To determine if p53 activation occurred in hematopoietic progenitors 
following Acd inactivation, we assessed expression of the p53 target genes Puma, Noxa 
and p21 within days after induction of Cre recombinase expression, but before 
hematopoietic progenitors were lost (Figure 5.8A). Acd deletion resulted in the 
upregulation of Noxa and p21 (Fig. 5.8B) but not Puma (data not shown) within 48 hours 
of poly(I:C) treatment. This effect was p53-dependent, as LSK progenitors from mice 
deficient for both Acd and p53 did not demonstrate upregulated expression of p21 and 
Noxa. Next, we assessed the cell cycle status of LSK progenitors shortly after Acd 
inactivation, in the presence or absence of p53 (Fig. 5.8C, D). Upon Tpp1 loss, we 
observed accumulation of hematopoietic progenitors in the G2/M phases of the cell cycle, 
consistent with the presence of G2/M arrest. Interestingly, this cell cycle arrest was 
observed even in the absence of p53. These data indicate that while p53 activation occurs 
acutely following Acd deletion, it is not required for G2/M arrest. 
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Figure 5.8. Acd inactivation results in acute cell cycle arrest and induction of p53 target genes.(A) 
Experimental design: Mx-Cre+Acd+/–, Mx-Cre+Acd+/–p53–/–, Mx-Cre+Acdfl/– and Mx-Cre+Acdfl/–p53–/– mice 
were injected with a single dose of poly(I:C) followed by BrdU, and sacrificed as indicated; (B) Relative 
abundance of p21 and Noxa transcripts in purified Lin–Scahic-Kithi (LSK) progenitors, demonstrating that 
Acd deletion induced a p53-dependent increase in p21 and Noxa mRNA (qRT-PCR; data are shown as 
mean ± SEM representative of at least 2 independently sorted samples per group); (C) Flow cytometric 
analysis of progenitors for BrdU incorporation and intracellular DAPI (icDAPI), showing accumulation of 
Mx-Cre+Acdfl/- and Mx-Cre+Acdfl/-p53-/- cells in G2/M phases of the cell cycle. Representative flow 
cytometry plots are shown from 4 independent experiments; (D) Quantification of data shown in (C) (n=3 
mice/group). *p<0.05, **p<0.01, ***p<0.001. 
Acd deficiency results in chromosomal fusions at telomeres in the absence of detectable 
telomere shortening.  
Acd-deficient embryonic fibroblasts display an increased rate of rare 
chromosomal fusion events involving telomeres. To evaluate if this occurred in 
hematopoietic tissues, we prepared metaphase spreads from control or Mx-Cre+ x Acdfl/– 
bone marrow cells within 48 hours after poly(I:C) administration (Figure 5.9A). This 
strategy ensured that dividing hematopoietic progenitors could be examined acutely after 
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Acd inactivation, while their numbers were still preserved. Efficient Cre-mediated 
excision was detected at the time of analysis (Figure 5.9B). Quantitative PCR showed 
that the amount of telomere signal was preserved at this stage in Mx-Cre+ x Acdfl/– bone 
marrow, consistent with the absence of telomere shortening within days of Tpp1 loss 
(Figure 5.9C). In contrast, FISH analysis revealed an increased frequency of metaphases 
in which chromosomal fusions were detected with a shared telomeric signal (Figure 
5.9D, E). These findings are consistent with Tpp1 loss driving the fusion of deprotected 
telomeric ends in dividing hematopoietic progenitors. 
	  
Figure 5.9. Acd-deficient hematopoietic progenitors demonstrate acute chromosomal instability in 
the absence of telomere shortening. (A) Experimental design: bone marrow was harvested from Mx-
Cre+Acd+/– or Mx-Cre+Acdfl/– mice 48 hours after a single dose of poly(I:C) and cultured overnight with IL-
3/IL-6/SCF. Metaphases were prepared after a 3 hour Colcemid treatment; (B) Relative abundance of exon 
7 DNA signal normalized to exon 2, showing rapid Cre-mediated excision in total bone marrow. 
***p<0.001; (C) qPCR assessment of telomere length in cultured bone marrow cells, showing preserved 
abundance of telomeric sequences acutely after Acd inactivation; (D) Representative pictures of metaphases 
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stained with DAPI and a FITC-labeled telomeric probe. Insert shows a chromosomal fusion event centered 
on a telomeric signal; (E) Blind scoring of metaphases, showing an increase in chromosome fusions 
containing a telomere signal among Mx-Cre+Acd fl/- metaphases. 
p53 inactivation does not rescue the function and maintenance of Acd-deficient 
hematopoietic stem cells. 
 Previous studies demonstrated that p53 inactivation rescued many features of 
abnormal development in acd hypomorphic mice [235, 236]. Furthermore, p53 
deficiency restored epidermal stem cell function following Acd inactivation [228]. To 
investigate if p53 inactivation could rescue HSC function and maintenance in the bone 
marrow following Acd deletion, we generated hematopoietic chimeras with wild-type 
CD45.1+ bone marrow and bone marrow from control CD45.2+ Mx-Cre+ x Acd+/– or Mx-
Cre+ x Acdfl/– mice, in the presence or absence of p53 (Figure 5.10A). After 
hematopoietic reconstitution, poly(I:C) was administered to induce Mx-Cre expression 
and Acd/Tpp1 inactivation specifically in the cohort of CD45.2+ hematopoietic cells. 
Mice transplanted with either Mx-Cre+Acdfl/– p53+/+ or Acdfl/- Mx-Cre+p53-/- progenitors 
lost all myeloid cells originating from the CD45.2+ graft within 2 weeks of Acd/Tpp1 
inactivation, and at all subsequent time points (Figure 5.10B). Additionally, CD45.2+ 
Acd-deficient T and B cells were progressively lost, irrespective of the presence of p53. 
At 16 weeks after poly(I:C) administration, flow cytometric analysis of the long-term 
HSC compartment demonstrated that Acd-deficient HSCs were completely depleted even 
in the presence of p53 inactivation (Figure 5.10C). In fact, analysis of the bone marrow 
revealed that numbers of Acd-deficient HSCs were already profoundly reduced within 1 
week of Acd inactivation, regardless of p53 status (Fig. 5.11). Altogether, p53 activation 
occurred acutely after loss of Tpp1 in hematopoietic progenitors. However, unlike in 
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epidermal stem cells and other cellular compartments, the maintenance and function of 
Acd/Tpp1-deficient HSCs could not be rescued by p53 inactivation. 
	  
Figure 5.10. p53 inactivation does not rescue the survival and function of Acd-deficient hematopoietic 
stem cells. (A) Experimental design: lethally irradiated B6-CD45.1 mice were transplanted with bone 
marrow (BM) from Mx-Cre+Acd+/–p53+/+, Mx-Cre+Acd+/–p53–/–, Mx-Cre+Acdfl/–p53+/+ or Mx-Cre+Acdfl/–
p53–/– B6-CD45.2+ and wild-type (WT) B6-CD45.1 competitor mice (5x105 cells each, 1:1 ratio). After 6 
weeks to allow hematopoietic reconstitution, poly(I:C) was administered; (B) Flow cytometric analysis of 
peripheral blood 2-16 weeks after poly(I:C), showing a rapid drop in contribution of the CD45.2+ Mx-
Cre+Acdfl/–p53+/+ and Mx-Cre+Acdfl/–p53–/– grafts to the myeloid (CD11b+Gr1+), T cell (CD3+) and B cell 
(CD19+B220+) compartments. Baseline chimerism was normalized to 100% in each mouse. The percentage 
of Mx-Cre+Acdfl/–p53+/+ and Mx-Cre+Acdfl/–p53–/–graft output differed significantly from Mx-Cre+Acd+/–
p53+/+and Mx-Cre+Acd+/–p53–/– output in the myeloid compartment by week 2 (p<0.001), in the T cell 
compartment by week 12 (p<0.01), and in the B cell compartment by week 8 (p<0.01). Data represent 
mean +/– SD (n≥4/group); (C) CD45.2/CD45.1 chimerism among long-term hematopoietic stem cells (LT-
HSC) 16 weeks after poly(I:C) administration, showing no residual CD45.2+ Mx-Cre+Acdfl/–p53+/+ or Mx-
Cre+Acdfl/–p53–/– HSCs. Representative flow cytometry plots are shown. Numbers indicate the percentage 
of cells in each gate. 
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Figure 5.11. p53 inactivation does not rescue Acd-deficient hematopoietic stem and progenitor cells 
from acute depletion. (A) Experimental design: lethally irradiated B6-CD45.1 mice were transplanted 
with bone marrow from Mx-Cre+Acd+/–p53+/+, Mx-Cre+Acd+/–p53–/–, Mx-Cre+Acdfl/–p53+/+ or Mx-
Cre+Acdfl/–p53–/– B6-CD45.2 and wild-type (WT) B6-CD45.1 competitor mice (106 cells each). After 6 
weeks to allow hematopoietic reconstitution, poly(I:C) was administered; (B) Flow cytometric analysis of 
bone marrow 5 days after starting poly(I:C) injection, demonstrating an acute depletion of Lineage–Sca-
1+cKithi (LSK) hematopoietic progenitors in both Mx-Cre+Acdfl/–p53+/+ and Mx-Cre+Acdfl/–p53–/– recipients 
(right panels). Representative flow cytometry plots are shown. Numbers indicate the percentage of cells in 
each gate. 
DISCUSSION 
Our findings demonstrate that hematopoietic stem cells are highly sensitive to 
shelterin deprotection initiated by Acd inactivation. Complete loss of the Acd gene 
product induced a surprisingly acute depletion of the fetal or adult blood-forming stem 
cell compartments, leading to rapid hematopoietic failure before telomere shortening 
could be detected. Although Tpp1 and the shelterin complex play dual functions in 
recruiting telomerase and in shielding telomeric ends from an uncontrolled DNA damage 
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response, our observations indicate that the overall effects of shelterin dysfunction in 
hematopoietic progenitors are dominated by acute telomere deprotection. Tpp1-deficient 
hematopoietic stem cells rapidly upregulated p53 target gene transcription and had 
evidence of cell cycle arrest and chromosomal instability. However, the maintenance of 
Tpp1-deficient stem cells was not rescued by p53 inactivation. These findings contrast to 
the major effects of Tpp1 loss on epidermal stem cell homeostasis and fetal 
musculoskeletal development, which are rescued in the absence of p53. Even without 
complete loss of Tpp1, as modeled by homozygosity for the hypomorphic acd allele, 
hematopoietic stem cell function was severely impaired. This demonstrates that blood-
forming stem cells are very sensitive to defects in telomere protection as compared to 
other tissues. 
Telomere deprotection has been shown to trigger a p53/p21-dependent cell cycle 
arrest [254]. Similarly, p53 activation has been shown to contribute to cellular senescence 
in response to critical telomere shortening [255-257]. These findings, combined with data 
demonstrating that p53 inactivation rescued epidermal stem cell defects owed to Acd 
inactivation led us to investigate the role of p53 in bone marrow failure in the setting of 
Acd deficiency [228]. We found that while Acd inactivation resulted in the increased 
transcription of p53 targets, indicating p53 activation, p53 deficiency did not rescue any 
component of the hematopoietic stem and progenitor defects that we tested. This included 
a failure to rescue acute cell cycle arrest, acute stem and progenitor depletion, and short 
and long-term functional deficiencies. These data indicate that p53 activation is not the 
predominant underlying cause of HSC functional defects or bone marrow failure 
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following Acd deletion, and suggests that different stem cell compartment may react with 
varying DNA damage responses in the setting of a telomere crisis. 
Telomere dysfunction has been hypothesized to play a role in multiple contexts 
including organ failure, aging and cancer. However, dyskeratosis congenita (DKC) is the 
prototypical human disorder most directly associated with defects in telomere 
homeostasis. DKC is a hereditary syndrome characterized by progressive telomere 
shortening. Although bone marrow failure is the most significant organ dysfunction and 
the leading cause of death in DKC, affected patients can also develop abnormalities in the 
skin, mucosal tissues, biliary tract and lungs, suggesting that multiple somatic stem cell 
compartments are affected. Mouse models of DKC have typically described gradual 
homeostatic dysfunction in rapidly proliferating tissues, and an eventual lethality due to 
the loss hematopoietic stem cells and bone marrow aplasia [60]. Upon reduced 
expression of Terc or Tert genes, progression to telomere crisis and stem cell loss 
typically occurs only after telomere attrition accumulates through several successive 
mouse generations [56]. With respect to shelterin components, a mouse syndrome 
reminiscent of DKC was first reported using combined Pot1b deficiency and Terc 
haploinsufficiency [223, 224]. In this model, a relatively mild DNA damage response and 
gradual telomere shortening have been identified as the drivers of hematopoietic failure. 
However, the significance of this model for human disease is limited because Pot1b is a 
mouse-specific shelterin component [218, 221]. Humans have a single POT1 protein that, 
if deleted, would yield a vigorous DNA damage response resulting not primarily in 
telomere erosion, but instead in acute telomere deprotection and a robust DNA damage 
response. Interestingly, human DKC patients with mutations in TIN2, the only shelterin 
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component thus far causally linked to DKC, have a particularly severe form of DKC with 
exceptionally short telomeres and a very early onset [241, 244, 247]. The acute nature of 
this form of DKC might be due to the fact that TIN2 mutations, like our Acd inactivation 
model, result in rapid telomere deprotection and destabilization, rather than the erosion 
observed in the Pot1b mouse model and in DKC patients in whom TERC or TERT are 
mutated. In fact, data in mouse embryonic fibroblasts indicate that the critical function of 
Tin2 is to stabilize the Tpp1-Pot1a/b complex at telomeres [238]. Progression towards 
stem cell loss may thus be significantly accelerated in the presence of shelterin mutations. 
It is estimated that up to 60% of DKC cases do not have a known underlying genetic 
defect [246]. Thus, it is interesting to speculate whether new shelterin genes mutations 
might be discovered in human DKC. Based on our results, we would predict that 
complete loss of shelterin function would not be compatible with life, as evidenced for 
example by in utero death upon complete loss of Acd in fetal hematopoiesis. However, it 
is possible that relevant mutations may decrease rather than abolish Acd expression. In 
mice, the hypomorphic acd splice variant was identified as a spontaneous mutation 
compatible with survival, but leading to a developmental syndrome with features 
reminiscent of DKC, including profound HSC dysfunction. These observations suggest 
that mutations in gene regulatory regions or in introns resulting in impaired gene 
expression ought to be considered when probing uncharacterized cases of DKC. 
Furthermore, recent studies have identified a specific protein-protein interface mediating 
a direct interaction between TERT and TPP1 that is critical for telomerase localization 
and processivity [230, 258]. It is possible that specific mutations affecting this interaction 
could affect the ability of TPP1 to recruit telomerase without disrupting its function in 
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preventing an uncontrolled DNA damage response, leading to a DKC-like phenotype. 
Finally, shelterin mutations may have to be considered in a broader range of human 
syndromes including in patients with early onset organ failure (as seen for TIN2 
mutations) and with developmental disorders not previously associated with shelterin 
dysfunction. 
A recent report has linked inactivation of the Trf1 shelterin gene to an acute form of 
bone marrow failure in mice [59]. These findings may be relevant to human disease, as 
TIN2 mutations in early onset DKC cluster in a region encoding a TRF1-binding site. 
Interestingly, Trf1 inactivation led to the rapid loss of hematopoietic progenitors and 
severe bone marrow failure, initially without detectable telomere shortening. When 
residual bone marrow cells were studied within 1-3 weeks after induction of Cre 
recombinase, increased compensatory proliferation was apparent, leading eventually to 
telomere shortening and p21 activation. These findings were proposed to underlie the 
pathogenic effects of shelterin mutations in human DKC through telomere deprotection, 
leading to rapid HSC loss. Our observations in Acd-deficient mice share key features with 
this report, including the profound HSC depletion independent of telomere shortening. 
However, near-complete HSC depletion was apparent in our study already within 5 days 
after Acd inactivation, with a detectable DNA damage response and cell cycle arrest 
evident within 48 hours. To capture the direct cellular and molecular consequences of 
shelterin deprotection, we focused on very early time points before affected HSCs are 
depleted, as evidenced for example by our detection of increased telomeric fusion events 
2-3 days after Tpp1 loss. Delaying analysis or decreasing the efficiency of target gene 
inactivation to preserve enough progenitors for study may lead a strong selection for cells 
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that escape Cre-mediated excision. In this situation, findings would focus on rare HSCs 
escaping inactivation and with functional shelterin that undergo major replicative stress, 
rather than on the direct effects of shelterin deprotection. It is possible that these 
considerations may account for differences in our observations on Acd deficiency and 
those reported on the effects of Trf1 inactivation. 
While it remains to be determined if Acd mutations contribute to human bone marrow 
failure and DKC, mouse models of telomere deprotection through Acd mutation or 
deletion suggest this possibility. Furthermore, the hyperacute nature of hematopoietic 
defects following Tpp1 loss provides a practical approach that could shed light on the 
consequences of telomere crisis in other models of bone marrow failure. Indeed, it is 
widely assumed that shortened telomeres induce a cellular crisis when their length 
becomes inadequate to recruit an efficient shelterin buffer, unleashing a DNA damage 
response that can cause cell cycle arrest, apoptosis or genetic instability. However, it is 
virtually impossible to study this pathogenic process directly in somatic stem cells of 
mice and patients, as telomere shortening occurs progressively and asynchronously in 
different stem cells over years in human patients and over several generations in classical 
mouse DKC models. Furthermore, relevant stem cell populations are by definition 
profoundly depleted by the time of diagnosis in patients with bone marrow failure. In 
contrast, our study provides a well-defined acute window of observation on a cohort of 
hematopoietic progenitors that simultaneously and acutely undergoes telomere 
deprotection. Thus, our study presents the first insight into very early hematopoietic 
defects that may predate bone marrow failure in DKC patients with shelterin mutations 
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and could be beneficial in developing a more complete understanding of the natural 
progression of human bone marrow failure syndromes. 
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CHAPTER 6.  CONCLUSIONS AND PERSPECTIVES 
Since Till and McCulloch’s initial discovery of hematopoietic stem cells, many 
researchers have tried to understand how these rare cells maintain hematopoiesis over a 
lifetime. It is clear that self-renewal plays a fundamental role in this long-term function, 
and as such significant research has sought to understand this property. In Chapter 1, we 
reviewed our current understanding of the extensive, diverse factors that contribute to 
HSC self-renewal, and as a result of the original work described in this dissertation, we 
have added our own novel insights into the regulation of this fundamental stem cell 
property. 
 Our work with Ash1l has demonstrated that this understudied TrG member plays 
an essential function in regulating bone marrow HSC self-renewal (Chapter 3). We 
identified that the paradigm of TrG member cooperation in developmental processes is 
conserved between flies and mammals. To date, the biochemical nature of this 
cooperativity has not been studied in any model. Given that both Mll1 and Ash1l are 
described as having catalytically active SET domains, it is tempting to speculate that 
cooperative SET domain activity promotes gene expression (Figure 6.1A). In this model, 
Mll1 H3K4 trimethylation activity could cooperate with Ash1l H3K36 dimethylation 
activity to promote robust target gene expression. Since Ash1l has not been detected in 
complex with Mll1, it is possible that both proteins are recruited to targets independently. 
Alternatively, the SET domain of Ash1l may be irrelevant for in vivo function. In this 
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case, Ash1l may be required for the recruitment of additional transcription factor(s) or 
epigenetic regulators and such factors may cooperate to promote gene expression 
independent of Ash1l SET domain activity (Figure 6.1 B). Since we currently lack good 
quality antibodies to detect Ash1l, it is possible that we lack sensitivity to detect 
complexes including Ash1l and Mll1. If this is true, it is possible that Ash1l is required 
for Mll1 recruitment or vise versa (Figure 6.1C). Our data suggest that this is unlikely as 
combined deficiency for Mll1 and Ash1l resulted in phenotypic worsening beyond the 
loss of either gene alone. If the products of these genes were required for the recruitment 
of one another, one would predict that such phenotypic amplification would not occur. 
These data do not rule out, however, that Ash1l and Mll1 are part of the same complex 
but do not directly recruit one another (Figure 6.1D). Significant biochemical studies will 
be required to examine the nature of this observed cooperativity and to test these 
hypothetical models. 
	  
Figure 6.1. Models for Ash1l cooperativity with Mll1. (A) Mll1 and Ash1l are recruited independently to 
target loci and cooperate through their respective SET domain activities. (B) Ash1l recruits additional 
transcription factor (s) that cooperates with Mll1 independent of Ash1l SET domain function. (C) Mll1 is 
required for Ash1l recruitment of vise versa. (D) Ash1l and Mll1 are recruited to the same protein complex 
which targets SET domain activities to target genes. 
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Profound hypomorphism for Ash1l resulted in a 5-10-fold LT-HSC reduction by 
young adulthood following an inability to establish a normal quiescent HSC pool. 
Importantly, our Ash1lGT allele is not completely null, although it is profoundly 
hypomorphic. It is possible that residual Ash1l expression from the Ash1lGT allele could 
mask additional phenotypes that would be revealed by the use of a truly null allele. For 
example, if only a low level of Ash1l is required for fetal hematopoiesis, a null allele may 
reveal additional fetal hematopoietic phenotypes not observed in our model. Assessing 
hematopoietic development with an Ash1l null allele may thus reveal differential 
sensitivities of fetal and adult hematopoietic stem and progenitor cells to Ash1l levels. 
This concept remains to be tested. 
Our data suggest that bone marrow HSC function is profoundly dependent on 
Ash1l.  The 5-10% of normal Ash1l transcripts present in Ash1lGT/GT HSCs were not 
sufficient to allow long-term HSC function in transplantation. This observation suggested 
that Ash1l-deficient mice could be destined to hematopoietic failure over time. 
Surprisingly, however, this did not occur. One could argue that the few remaining HSCs 
were sufficient to maintain hematopoiesis in primary mice, but could not engraft in the 
setting of transplantation due to hematopoietic stress or rarity. This latter possibility is 
unlikely, as even when HSC content was normalized by using fetal liver as the donor 
source, we could not identify functional Ash1lGT/GT HSCs. The former possibility is 
supported by the finding that residual Ash1lGT/GT HSCs diluted GFP more than wild-type 
in pulse-chase experiments. This could suggest that these rare cells increased their 
proliferative output to sustain hematopoiesis, though it remains to be determined if this 
increased proliferation was sufficient to support hematopoietic homeostasis. An 
	   111	  
additional and more intriguing possibility is that Ash1lGT/GT hematopoiesis is maintained 
predominantly from downstream progenitors that are not true LT-HSCs. Indeed, we 
could not detect long-term HSC function in transplantation, and this may reflect the 
absence of an LT-HSC compartment in the Ash1lGT/GT model. Our data may therefore 
question whether or not steady state hematopoietic homeostasis requires an LT-HSC 
population. 
 The terms long-term and short-term HSC are strictly based on function in bone 
marrow transplantation assays. Long-term HSCs were defined as cells capable of 
sustaining hematopoietic reconstitution of lethally irradiated mice in bone marrow 
transplantation assays for greater than 16 weeks [156, 259, 260]. Short-term HSCs were 
identified as providing robust, transient tri-lineage reconstitution but could not sustain 
reconstitution for 16 weeks [156, 158, 259, 260]. Due to these findings, LT-HSCs are 
viewed as the cells that possess self-renewal potential and maintain long-term 
hematopoietic homeostasis. The idea that LT-HSCs are required for steady-state 
hematopoiesis has never been addressed in the absence of transplantation, and thus 
remains a hypothesis. 
 A recent model of LT-HSC cell cycle activity indicated that long-term 
reconstituting potential was primarily maintained in HSCs that very rarely enter the cell 
cycle [161]. Phenotypic LT-HSCs that had divided only a few times had reduced long-
term reconstituting activity compared to undivided cells, and HSCs that had more 
extensively divided could not sustain long-term reconstitution. This was hypothesized to 
have occurred because dormant HSCs were the true LT-HSC population, and thus had 
more robust self-renewal activity. Mathematical models indicate that these dormant LT-
	   112	  
HSCs would divide ~5 times over the lifetime of a mouse. This finding may be 
inconsistent with dormant LT-HSCs contributing to the day-to-day turnover of 
hematopoietic tissue, though additional testing and mathematical modeling are required 
to evaluate this concept. 
Transplantation assays suggest that LT-HSC function resides almost exclusively 
in dormant HSCs, and this observation may parallel their support of steady-state 
hematopoiesis However, it is also possible that current transplantation methods are not 
suitable for adequately testing long-term potential or self-renewal in downstream 
progenitor populations.  Standard transplantation protocols do not allow one to 
distinguish between an inability to engraft and reduced self-renewal; both present as 
reduced tri-lineage output in the blood and reduced donor HSC detection at transplant 
termination. Indeed, several groups have reported that cycling HSCs were not as effective 
at long-term tri-lineage reconstitution as non-cycling HSCs in transplantation assays [29, 
154]. If prospective LT-HSCs were cultured and forced into S-G2-M, they engrafted 
poorly. If the culture conditions were extended such that the HSCs had time to transit 
through the cycle and re-enter G1, they could again engraft [29]. This suggested that cells 
did not lose self-renewal potential, but instead could not engraft the bone marrow if they 
were in late cell cycle stages. It would thus seem that reduced cell cycle entry correlates 
with better engraftability, and that transplantation assays do not always provide direct 
measurements of HSC self-renewal or stemness. Since downstream progenitors are 
actively cycling compared to dormant HSCs, this may impede our ability to test their 
long-term function in transplantation due to engraftment defects. 
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 Since we have historically defined LT-HSC function in transplantation assays, 
and we now know that cycling cells fail to achieve robust engraftment in transplantation, 
it follows that we may have far underestimated the frequency of cells capable of 
maintaining long-term hematopoiesis in steady-state conditions. We have thus defined 
LT-HSC potential under stress conditions, either through myeloablation or 
transplantation, and actually do not know the requirement for LT-HSC function during 
homeostasis. 
 By analogy, recent findings in T cell development can be informative when 
thinking about the requirement for classically defined primitive progenitor pools in 
developmental biology. A significant body of work based on transplantation studies 
suggested that thymic output required that the thymus be perpetually seeded with fresh 
progenitors. Until recently, the prevailing concept in the field was that this progenitor 
pool was needed because there were no self-renewing progenitors in the thymus, and thus 
all cells needed to be frequently turned over. Recent work demonstrates that self-renewal 
potential is actually present in the thymus under certain conditions [165, 166]. In the 
absence of progenitor import, existing thymic progenitors could self-renew and sustain 
thymic output. It was determined that in this system, if fresh progenitors were available, 
they could out-compete older thymic progenitors, promoting thymic turnover. However, 
if fresh progenitors were unavailable, these older intrathymic progenitors could sustain 
thymic output. 
 When considering our Ash1lGT/GT model in the context of the data presented in 
this thesis, we suggest a similar model to the T cell development studies described above. 
We could not detect functional LT-HSCs in transplantation, yet cells defined as being 
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ST-HSCs were present at normal frequencies, and hematopoietic output was largely 
preserved. It is possible that in the absence of fresh progenitors from the LT-HSC 
compartment, the ST-HSC compartment was capable of self-renewal and thus maintained 
hematopoietic homeostasis. At least two lines of evidence suggest that this may be true in 
the setting of Ash1l deficiency. Our non-ablative transplantation experiments 
demonstrated that if a healthy pool of LT-HSCs was made available to Ash1lGT/GT mice 
via transplantation, ST-HSCs were turned-over and these fresh LT-HSCs were then the 
major contributors to hematopoietic homeostasis. This is similar to what was reported in 
T cell development, although it has not been described thus far in HSC biology. 
Additionally, pulse-chase experiments demonstrated that progenitors downstream of LT-
HSCs were extensively cycling, presumably to maintain homeostasis. Despite this 
increased proliferation, these downstream progenitors were not depleted, as would be 
expected if these cells were strictly undergoing differentiating divisions to maintain 
mature cell populations. This increased proliferative capacity could thus be reflective of 
enhanced self-renewal potential. Therefore, loss of LT-HSCs in this model may have 
enhanced an intrinsic self-renewal capacity in downstream hematopoietic progenitors that 
cannot be assessed in standard transplantation. 
 This hypothesis would support a model in which LT-HSCs are capable of 
differentiating into ST-HSCs (Figure 7.1). These fresh ST-HSCs have not experienced 
the various DNA damage and metabolic stresses that older progenitors that have been 
engaged in cell cycle activity face. As a result, new ST-HSCs are more fit than older ST-
HSCs and outcompete them, resulting in turnover of the compartment. This would 
essentially suppress any self-renewal potential that ST-HSCs possess as they would not 
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be long-lived enough to demonstrate it. In the absence of LT-HSCs and this turnover, this 
block on ST-HSC self-renewal is removed. There are now no fresh progenitors to 
outcompete the older ones, and thus the self-renewal capacity of ST-HSCs is revealed. 
This hypothesis challenges the paradigm that LT-HSCs are required for long-term 
hematopoietic homeostasis under steady-state conditions. 
	  
Figure 6.2. Model of enhanced ST-HSC self-renewal in setting of reduced LT-HSC pool. In Ash1l-
sufficient hematopoiesis, LT-HSCs give rise to ST-HSCs and downstream progenitors. Self-renewal 
potential resides primarily in the LT-HSC pool. In ash1l-deficient hematopoiesis, the depletion of LT-
HSCs unmasks self-renewal activity in ST-HSCs, and these ST-HSCs maintain hematopoiesis. 
In a field where function in transplantation is the gold standard for identifying 
self-renewal, examining this hypothesis would require overcoming engraftment defects 
that are associated with cell cycle activity. One strategy could be retrovirally transducing 
hematopoietic progenitors with p27. p27 and p57 have been shown to cooperate in 
establishing quiescence, and p57 loss can be compensated by p27 expression [35, 36]. 
Since p57 has been linked to playing diverse roles in development, it is not a viable 
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candidate for these transduction studies [261]. p27 has not been linked to such processes, 
and thus could promote quiescence without disrupting development. We are currently 
developing reagents to perform such a study. 
 Quiescence preserves LT-HSC function through limiting exposure to proliferative 
stress. Such stress manifests itself in ROS accumulation, DNA damage, and 
leukemogenesis. While quiescence limits this damage, over the course of a lifetime, even 
largely dormant LT-HSCs sustain insults. Collectively, this damage results in 
hematopoietic aging (reviewed in [262]). Age-related decline in hematopoietic stem cell 
function results in reduced lymphoid output and reduced self-renewal activity [263]. One 
would predict acceleration in this aging process within actively dividing cell populations. 
The comparatively enhanced cell cycle activity of ST-HSCs relative to LT-HSCs in the 
setting of Ash1l deficiency suggests that our Ash1lGT/GT system may offer a new model in 
which to study aging. In data not shown in this dissertation, we have identified that 
Ash1lGT/GT mice have reduced lymphoid progenitor populations and early thymic 
involution, both of which are reminiscent of an aged hematopoietic system. Additional 
work will be required to assess age-related pathologies, including DNA damage, ROS 
accumulation, and predisposition to leukemia, in the context of Ash1l deficiency to 
determine the extent to which it models physiological aging. 
TPP1 and acute HSC depletion 
The loss of Tpp1 in LT-HSCs and hematopoietic progenitors resulted in an acute 
depletion of these cell populations (Chapter 5). Transplantation assays revealed a virtual 
absence of self-renewing LT-HSCs following Acd deletion. This acute sensitivity was not 
predicted by previous hematopoietic models of shelterin deficiency or telomere 
	   117	  
dysfunction [57, 60, 224]. In these models, decline in LT-HSC function was gradual and 
hematopoietic output developed progressively. This was the case because these models 
required telomere erosion secondary to proliferative stress to elucidate phenotypes. Even 
loss of the shelterin protein Trf1, while causing a more rapid decline in hematopoietic 
function than previous models, did not perturb LT-HSCs as acutely as did Tpp1 loss [59]. 
This leads one to consider that Tpp1 loss causes LT-HSC dysfunction in a manner that 
differs from previous models. 
MEF studies indicated that Tpp1 deficiency should activate an ATR-dependent 
DNA damage response [215]. However, ATR activation is unlikely to affect such an 
acute depletion of cells, especially those that are quiescent. ATR is activated by stalled 
DNA replication forks, and thus requires active DNA replication for activation. This 
typically means that ATR is activated in S phase. Since adult LT-HSCs do not uniformly 
enter the cell cycle and are only rarely in later S-G2-M phases of the cell cycle, ATR 
activation is unlikely to be the sole mode of LT-HSC depletion in the Acd-deficient 
model. 
Our initial identification of upregulation of the p53 target genes p21 and noxa 
following Acd deletion suggested that p53 mediated cell cycle arrest and apoptosis could 
have significantly contributed to LT-HSC functional decline. This was consistent with the 
p53-dependent functional decline of skin stem cells in the absence of Tpp1, as well as the 
rescue of many developmental abnormalities attributed to acd hypomorphism by p53 loss 
[228, 235, 236]. However, despite robust activation of p53 target genes following Acd 
deletion, p53 deficiency did not rescue LT-HSC function nor did it slow LT-HSC and 
progenitor depletion. Thus, p53 was not the primary cause of LT-HSC dysfunction 
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following Tpp1 loss. These findings demonstrate potential tissue-specific functions of 
shelterin proteins. 
One intriguing possibility is that Tpp1 loss results in mitochondrial dysfunction. 
Telomere shortening has been linked to mitochondrial failure and ROS accumulation, 
both of which would compromise even quiescent LT-HSCs [264]. ROS accumulation has 
been shown to trigger cell death independently of p53 through p38/MAPK activation. 
Indeed the shelterin protein Tin2 has been shown to contribute to mitochondrial function 
through an unclear mechanism. Preliminary work from our lab has identified activation 
of the intrinsic (mitochondrial) pathway of apoptosis following Acd deletion even in the 
absence of p53. We are currently developing techniques to assess mitochondrial function 
to evaluate this possibility. 
Understanding the mechanisms through which Tpp1 loss results in hematopoietic 
failure has direct implications for human disease. The recent identification of TIN2 
mutations in the human bone marrow failure syndrome dyskeratosis congenita 
necessitates such studies. TIN2 mutations result in a very aggressive form of the disease 
with an early onset. It thus does not follow a progressive model similar to other forms of 
the disease associated with telomere erosion. In the shelterin complex, one of the primary 
functions of Tin2 is tethering Tpp1/Pot1 to Trf1 and Trf2. Tin2 loss is embryonic lethal 
in mouse studies, and no conditional allele has been described. Tpp1 loss is therefore the 
most accurate reflection of what may happen when TIN2 is mutated in human patients. 
Understanding how Acd deficiency affects stem cell compartments, not just in the 
hematopoietic system but throughout development and across tissues, may direct 
therapeutic interventions in treating patients. 
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CHAPTER 7.  MATERIALS AND METHODS 
Mice used for general transplantation assays. C57BL/6 (B6, CD45.2+) mice were 
purchased from Harlan (Indianapolis, IN) and C57BL/6.Ptprca (B6-SJL, CD45.1+) were 
purchased from the National Cancer Institute (Frederick, MD).  
 
Mice used for Acd studies. acd hypomorphic mutant mice and mice carrying a floxed 
conditional Acd/Tpp1 allele (Acdfl) have been described previously [215, 234]. Acdfl/+ 
mice were crossed with mice carrying a null Acd allele (Acd–) and Mx-Cre [251], Vav-
Cre transgenic [265]or Cre-ERT2 lentitransgenic mice [252]. When indicated, mice were 
crossed onto a p53–/– background [266]. To fully inactivate Acd/Tpp1, Cre-expressing 
Acdfl/– mice were used. Mx-Cre activation was initially achieved via 5 intraperitoneal 
injections of 200 µg poly(I:C) (EMD Biosciences, Billerica, MA). To better capture acute 
changes induced by Acd/Tpp1 loss in hematopoietic stem and progenitor cells, we used a 
single 20 µg dose of highly purified poly(I:C) (GE Healthcare Biosciences, Pittsburgh, 
PA). This allowed detection of hematopoietic progenitors soon after administration with 
minimal effects on their phenotypic profile from the poly(I:C)-mediated interferon 
response. Cre-ERT2 activation was achieved by 2-3 intraperitoneal injections of 
tamoxifen in corn oil (Sigma, St. Louis, MO; 1 mg/dose). The University of Michigan 
Committee on Use and Care of Animals approved all experiments. 
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Mice used for Ash1l studies. Ash1lGT embryonic stem cells were obtained from the 
Wellcome Trust Sanger Institute (Hinxton, England). ES cells were injected into 
blastocysts, and mice were generated by The University of Michigan Transgenic Animal 
Core. To study the fetal to adult transition, Ash1lGT/+ mice were bred with Sox17GFP/+ 
mice [26]. To perform long-term pulse-chase experiments, Ash1lGT/+ mice were bred with 
transgenic animals containing both Rosa26-rtTA and TetOP-H2B-GFP as previously 
described [161, 267]. To label hematopoietic cells with GFP, animals were maintained on 
doxycycline (2mg/ml) for 6 weeks. Following this labeling period, doxycycline drinking 
water was removed and animals were maintained on normal drinking water for a 6 week 
chase period to allow GFP dilution in dividing cells. 
For experiments examining cooperativity between Ash1l and menin/Mll1, 
previously described transgenic Men1fl mice were bred to generate Ash1lGT/GTMen1fl/flMx-
Cre+ mice and additional indicated genotypes [163]. Men1 excision was achieved by 
intraperitoneal injection of 5 doses of 50ug poly (I:C) administered every other day. The 
University of Michigan Committee on Use and Care of Animals approved all 
experiments. 
 
Flow cytometry. Fetal liver and bone marrow specimens were harvested and single cell 
suspensions were prepared. Red blood cells were lysed with ACK lysis buffer (Cambrex, 
Walkersville, MD) and counted with a hemacytometer or a Nexcelom AutoT4 Cellometer 
(Nexcelom, Lawrence, MA). The following antibodies were from BioLegend (San Diego, 
CA), eBiosciences (San Diego, CA) or BD Biosciences (San Jose, CA): anti-CD3, CD4, 
CD8, CD11b, CD11c, CD19, CD48, CD150, Gr1/Ly-6G, B220, NK1.1, TCRβ, TCRγδ, 
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c-Kit and Sca-1. We used the following antibody cocktail to exclude Lineage+ cells: anti-
CD11b, Gr1, CD11c, B220, CD19, CD3, TCRβ, TCRγδ, CD8, NK1.1 and Ter119. BrdU 
analysis was performed using a BrdU labeling kit (BD Biosciences). Ki67 staining was 
achieved using the BD Ki67 Set (BD Biosciences). Annexin-V staining was performed 
using an Annexin-V labeling kit (BD Biosciences). Analysis was on FACSCanto and 
sorting on FACSAria II/III (BD Biosciences). Dead cells were excluded with 4′6-
diamidino-2-phenylindole (Sigma). Files were analyzed in FlowJo (Tree Star, San Carlos, 
CA). 
 
Bone marrow and fetal liver cell transplantation. 6-8 week old B6-SJL (CD45.1+) 
recipient mice were lethally irradiated (900 Gy, 37Cs source). Four hours after irradiation, 
mice were transplanted with the indicated donor bone marrow or fetal liver cells via tail 
vein injection. For competitive transplantation, we mixed equal numbers of competitor 
B6-SJL bone marrow and tester CD45.2+ bone marrow or fetal liver cells. For non-
ablative transplantation, 5-8 week old Ash1lGT/GT or wild-type controls were injected via 
tail vein 2 X with 2.0 X 107 B6-SJL (CD45.1+) bone marrow cells. Injections were 
separated by 1 week. 
 
Complete blood counts. Blood was obtained through retroorbital bleeding and 
transferred to EDTA-treated tubes. Complete blood counts were determined by analyzing 
the samples on the Advia 120 Hematology System (Siemens, Malvern, PA). 
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Quantitative Real-Time PCR. For gene expression analyses, at least 5000 Lin–Scahic-
Kithi (LSK) hematopoietic progenitors were sort-purified directly into Trizol (Invitrogen, 
Carlsbad, CA). After RNA extraction, cDNA was generated using the SuperScript III 
First Strand Synthesis Kit (Invitrogen) or the Nugen Ovation PicoSL WTA System 
(Nugen Technologies, San Carlos, CA). Relative gene expression was measured using 
Taqman (Applied Biosystems, Carlsbad, CA) primer and probe sets or SybrGreen 
(Fisher, Rockford, IL) for the indicated target genes. Reactions were carried out on a 
Mastercycler realplex (Eppendorf, Westbury, NY). Relative expression was calculated 
after normalization with Hprt1 expression using the ΔΔCT method. Primer information is 
listed in Table 7.1.  
For quantification of Acd excision, 10000 LSK progenitors were sort-purified into 
Direct Lysis buffer (Viagen Biotech, Los Angeles, CA) with 1 µL Proteinase K. Samples 
were incubated overnight and Proteinase K was inactivated at 85oC for 1hr. To assess 
excision, we used a primer pair specific for the floxed Acd exon 7 and an exon 2-specific 
primer pair amplifying a DNA sequence outside the floxed region. Amplification was 
performed with SybrGreen (Fisher, Rockford, IL) before quantification of exon7/exon2 
signal on Mastercycler realplex using the ΔΔCT method. For measurement of telomere 
length, DNA was extracted with Direct Lysis buffer as described above. Primers specific 
for telomeric DNA and the reference locus m36b4 were used with SybrGreen 
amplification on Mastercycler realplex, as described [268, 269]. The abundance of 
telomeric DNA normalized to m36b4 signal was calculated using the ΔΔCT method. 
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Table 7.1. qPCR Primers 
Target Primer Sequence or TaqMan Assay ID Format 
Acd Exon 2 F-TACTCCAGGACTCGGAGACT  
R-TCTGACACAAGTAACACGGC 
SybrGreen 
Acd Exon 7 F-CTAACCCTGTCCCAGCTTCT 
R-TACAAGGACCTTTCAGCACC 
SybrGreen 
Ash1l Mm01212715_m1 TaqMan 
Hoxa5 Mm00439362_m1 TaqMan 
Hoxa7 Mm00657963_m1 TaqMan 
Hoxa9 Mm00439364_m1 TaqMan 
Hoxa10 Mm00433966_m1 TaqMan 
Hprt1 Mm01545399_m1 TaqMan 
m36b4 F-ACTGGTCTAGGACCCGAGAAG 
R-TCAATGGTGCCTCTGGAGATT 
SybrGreen 
Meis1 Mm00487664_m1 TaqMan 
Noxa Mm00451763_m1  
p21 Mm00432448_m1 TaqMan 
p27 Mm00438168_m1 TaqMan 
p57 Mm00438170_m1 TaqMan 
Puma Mm00519268_m1  
Telomere F-CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT  
R-GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT 
SybrGreen 
 
Metaphase preparation and analysis. Bone marrow cells were cultured for 12 hours in 
S-clone SF-O3 medium (Iwai, Foster City, CA) with IL-3 (9 ng/ml), IL-6 (5 ng/ml) and 
stem cell factor (100 ng/ml) (Peprotech, Rocky Hill, NJ) at 5%CO2 and 37oC. 
KARYOMax Colcemid (Invitrogen) was added at 0.2µg/mL for 3-4 hours at 37oC. 
Metaphase spreads were then prepared as described [270]. Samples were stained with a 
PNA-TelG-FITC probe (Biosynthesis, Lewisville, TX) and DAPI as previously 
described. Metaphases were analyzed and images acquired using a Nikon E800 
microscope equipped with an Olympus DP-71 digital camera. Images were scored in a 
blinded fashion. 
 
CFU-GM and single-colony PCR. 20000 bone marrow cells were plated per mL of 
Methocult GF M3534 (Stem Cell Technologies, Vancouver, BC). Colonies were scored 
7-10 days later. Where indicated, individual colonies were removed as a plug with 
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methylcellulose and washed in PBS before DNA extraction in 100uL lysis buffer 
(Viagen) with 1uL proteinase K. Samples were incubated overnight and Proteinase K was 
inactivated at 85oC for 1hr. Colony DNA was then genotyped as described (Kibe, 2010). 
 
Statistical analysis. Comparison of two means was performed with 2-tailed unpaired 
Student t test. Analysis of more than two means was performed with ANOVA followed 
by Bonferroni post-test analysis. Comparisons of observed genotypes to those predicted 
by Mendelian ratios were performed with Chi Squared analysis. 
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